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ABSTRACT 
Kent Ross Gordon: Tools for the Advancement of Cell-based Screening for 
Neurological Disorders 
(Under the direction of Anne Marion Taylor) 
 
 The pharmaceutical industry has changed in multiple ways.  Major 
consolidation has continued with increasing mergers and acquisitions.  Concurrently, 
there has been a decreasing trend in the number of new drugs being 
commercialized.  Of this reduced output, new drug discovery has increasingly 
focused on treatment of neurological disorders, and R&D outsourcing has increased 
in the form of partnerships with academic drug discovery centers.  As public 
institutions, it is critical for these partnerships to have low cost solutions for their drug 
discovery needs.  In this spirit new focus has been directed at developing technology 
to improve drug screening for neurological diseases.  This new technology includes 
microfluidic devices for increasing throughput as well as the use of human induced 
pluripotent stem cell (iPSC) derived neurons which present an advantage over 
animals for modeling human diseases.  Although they show great promise, human 
iPSC-derived neurons are still hindered by many challenges, including long 
differentiation times and low yields of homogenous neuronal subtypes.  These 
challenges along with the post-mitotic nature of other mature primary neurons limit 
the pool of available cells for screening.  Historically this has been addressed by 
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using immortalized non-neuronal cell lines in neurological screening; however 
screening on neurons represents the possibility of better outcomes due to their 
phenotypic and morphological accuracy.  Thus there is an increased demand for 
technology to expand neuron throughput for screening.  This work explores the use 
of microraft arrays to increase throughput for neuron-based neurological disorder 
drug screening.  Microraft arrays are culture devices consisting of an array of 1,600 
releasable, paramagnetic, polystyrene microrafts (500 µm x 500 µm x 100 µm) each 
serving as an individual culture surface.  The device is used to culture both primary 
rat neurons as well as human neurons derived from embryonic stem cells, and new 
tools are created to support this device for screening applications.  Individual 
microraft cultures were maintained in multi-well plates and tools were developed to 
isolate and transport of individual microrafts to facilitate screening studies.  
Centering and quantification of these microrafts was achieved and together these 
results show a strong potential for the use of this device in neurological screening. 
Finally, in order to demonstrate the high-throughput potential of this technology, 
scalable assays including a bead-based ELISA and an immunofluorescence assay 
are devised to detect fragile X mental retardation protein which is reduced in patients 
with fragile X syndrome – a well-known neurodevelopmental disorder. 
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Chapter 1 Background 
1.1 Introduction 
Neurological disorders including neurodevelopmental and neurodegenerative 
diseases represent a disease segment with one of the largest unmet need.  While 
undergoing many structural changes, the pharmaceutical industry is now focusing 
more intensely on this disease segment.  For these reasons, new technology is 
needed to reduce costs.  The technology to-date however has yet to make a strong 
impact on drug discovery and here we learn why this is the case.  In this review, an 
assessment is made of the current state of treatment for neurological diseases 
followed by the current state of pharmaceutical R&D.  Finally, new technological 
solutions including physical devices and cellular innovations are described along 
with their implementation. 
1.2 Current State of Treatment for Neurological Diseases 
There are many neurological disorders without cures or effective treatments.  
This is the case for a variety of reasons.  In some cases the specific cause of the 
disease or disorder is unknown, so there are no reliable biomarkers from which a 
treatment can be based.  Examples of this include Amyotrophic Lateral Sclerosis 
(ALS) and late onset Alzheimer’s disease.  In other cases potential treatments have 
failed in clinical trials either because they were found ineffective or toxic such as the 
failure of CEP-1347, the apoptosis kinase inhibitor, which failed to show efficacy in 
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phase II clinical trials for the treatment of Parkinson’s disease.1  Data has shown an 
increase in attrition rates for new pharmaceutical projects across all phases, but 
especially Phase II and III clinical trials.2  One of the reasons for these increased 
attrition rates is the discrepancies between the animal models used in preclinical 
trials and human subjects used in later clinical trials.  Another reason is that 
screening and preclinical work has not been carried out because it is not financially 
practical for most organizations. 
Of the many neurological diseases and disorders, the ones that can benefit 
the most from new cost saving technology are those in which well-defined 
biomarkers exist, and are simple in nature such as single gene mutations or those in 
which a known protein is absent or over expressed.  For these reasons, some of the 
most attractive disorders for drug discovery include Huntington’s disease (HD), 
Fragile X Syndrome (FXS), Duchenne Muscular Dystrophy (DMD), Spinal Muscular 
Atrophy (SMA), and Friedreich’s ataxia (FRDA). 
None of these diseases and disorders has a cure and a possible reason for 
this is the lack of preclinical testing on human cells.  Currently the largest 
impediment to testing with human cells is access.  Unless testing can be done on 
skin fibroblasts or muscle myocytes which are relatively easy to access, currently the 
only source for diseased neurons comes from post mortem patients.  However, 
these cells are not easily accessible, only represent a particular stage of maturity, 
and are subject to certain ethical issues.  Embryonic stem cell (ESC) derived 
neurons are also hindered by ethical issues.  Human induced pluripotent stem cell 
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(hiPSC) derived neurons present a promising alternative and will be described in a 
later section. 
1.2.1 Huntington’s Disease 
Huntington’s disease is an autosomal dominant neurodegenerative disorder 
caused by a CAG repeat expansion in the huntingtin gene.  This mutation results in 
an expanded polyglutamine (polyQ) repeat in the huntingtin protein (HTT).  Repeats 
>36-39 trigger the disorder and longer expansions lead to an early onset.3; 4  The 
polyQ repeat expansion leads to a buildup of misfolded HTT which is toxic to 
neurons in the central nervous system (CNS). 
HD is an inherited disorder that typically begins between the ages of 30 to 50 
and gets progressively worse after onset.  This disease is characterized by 
uncontrollable motor functions, known as chorea, and cognitive deficits in patients.  
The impairment in cognition includes attention deficit and loss of short- and long-
term memory as well as reduced depth perception.5  Other symptoms include slurred 
speech, emotional instability, and difficulty feeding and swallowing. 
There is no cure for HD and current treatments only treat symptoms.  So far 
the most successful drug used to treat HD is Tetrabenazine (Zenazine) by 
Lundbeck.  Tetrabenazine, a high-affinity inhibitor of mono-amine uptake into 
vesicles of presynaptic neurons, was approved in 2008 for chorea in HD patients.6  
Looking at the current pipeline (Table 1.1), therapeutic approaches for HD include 
addressing mutant HTT modification and degradation, addressing signaling 
pathways, and reducing mutant HTT through inhibition of gene transcription or 
mRNA translation.  Some of these therapeutic strategies are encouraging, but still 
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very early in development.  The major drugs that have failed in the pipeline include 
Dimebon (Latrepirdine), Coenzyme Q10, PDE10A Inhibitor, Pridopidine, VX15, and 
PBF-999.  All of these drugs failed in phase II or III trials suggesting that they were 
non-toxic but ineffective.  It’s possible that this lack of efficacy could be due to the 
failure to test these compounds on human cells prior to entering the clinic.  In 
preclinical studies, Dimebon and Coenzyme Q10 were tested on the YAC128 HD 
transgenic mouse while the PDE10A inhibitor was tested on the R6/2 HD mouse 
model.  Pridopidine was tested on CHO cells expressing human D2short dopamine 
receptors. 
 1.2.2 Fragile X syndrome 
Fragile X syndrome (FXS) is well known neurodevelopmental disorder and 
one of the leading causes of autism.  FXS is caused by a CGG repeat expansion in 
the 5’ untranslated region of the fragile X mental retardation 1 (FMR1) gene located 
on the X chromosome.  This mutation leads to loss of the fragile X mental 
retardation protein (FMRP).  FMRP is a ribonucleic acid (RNA) binding protein which 
serves to transport intracellular RNA and regulate the translation of target 
messenger RNAs (mRNA). 
FXS is the most common form of inherited mental retardation.  FXS also 
makes up the largest percentage of cases of syndromic autism spectrum disorder 
(ASD) and affects 1 in 5,000 males and 1 in 6,000 females.7  Individuals having over 
200 repeats, typically ~800 repeats, are considered to have the full mutation and 
lead to complete silencing of the FMR1 gene, while those with 55-200 repeats are 
said have the premutation.  For the fully mutated FXS patients , symptoms include 
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moderate to severe mental retardation, delays in social development, attention 
deficit, hyperactivity, anxiety, reduced motor coordination, and an increased 
incidence of epilepsy.8  
Currently there is no cure for FXS.  Most current therapies target anxiety and 
other symptoms rather than addressing the root cause of the disease.  Treatments in 
the pipeline (Table 1.2) for FXS target neuro-transmitter dependent receptors, cell 
signaling molecules, translation regulators, and specific targets of FMRP.  In terms 
of these potential treatments, major clinical failures include Arbaclofen, Basimglurant 
(RO4917523), and Mavoglurant (AFQ056).  Arbaclofen is a GABA-B agonist while 
Basimglurant (RO4917523) and Mavoglurant (AFQ056) are both mGlur5 
antagonists.  These are all neuro receptor ligands and instead of addressing the root 
cause of the disease, they only function to ameliorate the FXS phenotype 
downstream at neural synapses.  Most importantly however, all three of these 
therapies were tested on the fmr1 knockout mouse model in preclinical studies and 
not on human cells. 
 1.2.3 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is the most common form of muscular 
dystrophy and the most common neuromuscular disease.  DMD is caused by 
disruptions in the DMD gene which consists of 79 exons on the X chromosome.  
These disruptions include deletions (~65%), duplications (~10%), point mutations 
(~10%), and other rearrangements (15%), and lead to the loss of the protein, 
dystrophin, for which it encodes.  Dystrophin is present in all types of muscle as well 
as neurons and is among a family of membrane cytoskeletal proteins.9-11  
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DMD affects 1 in 3,500 boys and is first observed at the age of 3 to 5 years.  
From onset, the disease is characterized by rapid progression of muscle weakness 
and degeneration.  By the age of 12 most boys lose the ability to walk and death 
occurs by the age of 20 or 30 usually due to respiratory failure. Girls have a 50 
percent chance of inheriting and passing the defective gene to their children.11-13  
There is no cure for DMD.  Glucocorticoid drug therapy represents the best 
therapeutic option.  Examples of this family of drugs include the corticosteroids, 
prednisone, and deflazacort.  These drugs unfortunately have many side effects, but 
are effective in slowing the rate of muscle deterioration, reducing inflammation, and 
delaying the disease progression overall.  Furthermore, it is not yet clear 
mechanistically how these drugs function to ameliorate the symptoms of DMD.11  
Current therapeutic research for DMD can be divided into two approaches – 
therapies that attempt to upregulate dystrophin production and those that attempt to 
treat specific phenotypes of the disease.  Methods used to restore dystrophin 
include cell therapy, gene therapy, exon skipping, and suppression of stop codons, 
while those used to treat the disease phenotypic side effects include anti-
inflammatory, anti-fibrotic, and antioxidant agents, myostatin pathway inhibition, 
neuronal nitric oxide synthase (NNOS) pathway enhancement, and Utrophin 
upregulation. 
There are many therapies currently in clinical trials for DMD (Table 1.3); 
however there have also been many failures.  These failures include GSK2402968 
(Pro-051), Tadalafil, Drisapersen, ACE-031, PTC124 (Ataluren), BMN053 (Pro-053), 
BMN044 (Pro-044), and halofuginone (HT-100).  GSK2402968 (Pro-051) is a 2OMe 
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oligomer, Tadalafil is a GMP-hydrolyzing phosphodiesterase 5A (PDE5A) inhibitor, 
Drisapersen is a 2’O-methyl-phosphorothioate oligonucleotide (2’OMePS) which is a 
type of antisense oligonucleotide targeting exon 51, ACE-031 is a muscle growth 
factor, PTC124 (Ataluren) is a stop codon suppressor, BMN053 (Pro-053) is a 
2’OMePS targeting exon 53, BMN044 (Pro-044) is a 2’OMePS targeting exon 44, 
and halofuginone (HT-100) is an anti-fibrotic TGF-β inhibitor.  The majority of these 
therapies were tested on human myoblasts except for Tadalafil and halofuginon (HT-
100) which were tested on the mdx mouse model.14-16  
 1.2.4 Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by 
mutation or deletion of the survival motor neuron (SMN) 1 gene which leads to a 
reduction or loss of the SMN protein.  The function of the SMN protein includes RNA 
transcription, pre-mRNA splicing, small nuclear ribonucleoprotein (snRNP) 
biogenesis, axonal transport, and cytoskeletal dynamics.17  Humans also possess an 
SMN2 gene which is paralogous to SMN1 with the exception of a translational 
silence occurring at nucleotide 840 which leads to alternative splicing.  The majority 
of the SMN protein is therefore produced by SMN1 however SMN2 does produce 
low levels of the protein.  Loss of the SMN protein leads to degradation of motor 
neurons in the spinal cord. 
Spinal muscular atrophy affects approximately 1 in 10,000 newborns and is 
considered the second most common fatal autosomal recessive disorder.18  There 
are three types of SMA and all result in weakness and degradation of muscles 
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located in the trunk and distal limbs, thus causing difficulties in breathing and 
movement. 
There is no cure for SMA.  Current therapeutic research on SMA has focused 
on four major therapeutic approaches.  These approaches include replacement or 
correction of the mutated SMN1 gene, modulation of the SMN2 gene, 
neuroprotection of distressed motor neurons, and prevention and restoration of 
muscle function loss.  
Currently 4-AP (Dalfampridine-ER, Ampyra) is showing the most promise in 
clinical trials.  This drug has been approved to treat muscle fatigue in patients with 
multiple sclerosis and is sold and produced by Acorda Therapeutics.19  Although the 
studies on SMA have been completed successfully, Chiriboga et al. from Columbia 
University found no positive improvement in motor function or ambulation in adults 
ages 18-50 at the doses approved for muscular sclerosis.20 
SMA has seen two therapeutic failures in Phase I clinical trials suggesting 
issues with toxicity (Table 1.4).  These failures include the small molecules LM1070 
by Novartis, and RG7800 (RO7034067, RO6885247) by Roche and PTC 
Pharmaceuticals.  LMI070 (NVS-SM1) is an SMN2-splicing modulator and was 
tested on the C/+ SMA mouse model in preclinical studies.21  RG7800 (RO7034067, 
RO6885247) is also an SMN2-splicing modulator, however preclinical studies of this 
compound were tested on the Δ7 SMA mouse model as well as Islet-1+ hiPSC-
derived motor neurons.22 
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1.2.5 Friedreich’s Ataxia 
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative 
disease caused by a mutated expansion of the guanine-adenine-adenine (GAA) 
triplet on both alleles of the frataxin (FXN) gene.  This is a heterogeneous disease 
with a range of 600 to 1200 repeats.  This mutation leads to loss and reduced 
expression of the protein frataxin which is produced in the mitochondria and is 
involved in iron metabolism within the cell and also has antioxydative properties.  A 
loss of FXN protein leads to dysfunction in ATP synthesis, iron accumulation, 
possible oxidative stress, and cellular dysfunction as a whole.23; 24  
FRDA is the most common form of hereditary ataxia.  In the United States 
approximately 1 in 100 people are carriers of the mutated FXN gene and one in 
20,000 to 50,000 are affected.  Symptoms of the disease include loss of coordination 
(ataxia), fatigue, loss of vision, loss of hearing, impaired speech, aggressive 
scoliosis, diabetes mellitus, and serious heart conditions including hypertrophic 
cardiomyopathy. These symptoms usually begin between the ages of 5 and 25 but 
occasionally begin in middle aged adults.  Most people diagnosed with the disease 
require walking aids such as a wheelchair by their early 20s.25; 26 
Therapeutic research for FRDA has focused on mitochondrial function, 
oxidative stress, upregulation of FXN, gene therapy, and neurotrophic factors. 
FRDA has seen many drug failures in recent years.  These include the 
antioxidents Idebenone and alpha-tocopherolquinone, the FXN modulators 
Interferon-ɣ and Lu-AA24493, the iron chelator deferiprone, pioglitazone, EGB761, 
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and verenicline.  While many of these drugs were tested on human fibroblasts in 
preclinical studies, none were tested on human motor neurons. 
 All of the above mentioned diseases and disorders lack a cure.  Drugs have 
continued to fail in the regulatory pipeline, and in most of these cases preclinical 
studies were performed on non-human cells.  Drug screening using human cells 
may improve the identification of drugs that are effective in humans.  Thus there is 
an obvious need for new technologies to make preclinical studies on human cells 
more feasible and help pave the way for cures for such diseases. 
1.3 Current State of Commercial Drug Discovery R&D 
1.3.1 Current State of Pharmaceutical R&D and Future Directions 
 The pharmaceutical industry has undergone many changes over the last half 
century.  After adjusting for inflation, the cost to bring a new drug to market in the 
1980’s was approximately $400 MM, and took 7 years, while today it’s close to $2.6 
B and requires 15 years.27  These increased costs can be attributed to the rising 
costs of Phase II and Phase III clinical trials.  Furthermore, where clinical costs were 
less than pre-human studies in the 1980s to early 1990s, clinical studies have risen 
in cost dramatically over the past twenty years.27  
The industry is also undergoing increased levels of consolidation.  From 1988 
to 2011 the membership of the Pharmaceutical Research and Manufacturers of 
America (PhRMA) organization saw a 75% reduction largely because of mergers 
and acquisitions (M&A) in the industry.  Some examples of major M&A deals during 
this time include that of Brystol-Myers and Squibb in 1989, Glaxo and Smith-Kline in 
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2000, and Pfizer (Warner-Lambert, Pharmacia) and Wyeth in 2009.  Taking 
advantaged of synergies, this increased consolidation has led to cuts in R&D and 
some argue the decline in output efficiency.28  
 Reduced efficiency has been a major topic in the Pharmaceutical industry in 
the past twenty years.  The number of new drugs approved per billion US dollars 
spent on R&D has been in a broad decline since 1950 (Figure 1.1), and taken as 
just the new drugs approved, this number has been mainly flat (Figure 1.2). 
As mentioned above, one possible reason for stagnation is due to industry 
consolidation.  Between 1990 and 1999 there was an average of 31 drugs approved 
per year compared to 24 drugs from the years 2000 to 2009.  This number peaked in 
1996 with 54 drugs, but many of the companies that existed back then do not exist 
today.28  
 Another possible reason for the decline in efficiency is associated with the 
idea of “low hanging fruit”.  This theory follows the notion that the technically 
tractable drugs such as the cardiovascular statins of the ‘90s have already been 
developed and the diseases that remain to be treated are much more difficult to 
develop drugs for.  This concept somewhat discounts the efforts that went into 
developing early drugs and fails to account for the fact that successfully 
commercialized drugs raise the standards and lower the value of undiscovered 
drugs.  It does however point to the treatment of neurological diseases as the future 
of drug discovery next to cancer therapies.2; 29-31  From 2000-2007, nervous system 
focused R&D increased 1.09% compared to -4.57% for the cardiovascular system.2  
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However, due to a lack of pathological understanding as well as disease 
heterogeneity, treatment of neurological diseases faces a much steeper path. 
1.3.2 Public Private Partnerships in Drug Development 
With continued consolidation and the growing costs of R&D, companies are 
increasingly outsourcing R&D efforts to help preserve profits and minimize their risk 
in the market.  These public-private partnerships (PPP) can exist between 
pharmaceutical companies and academic institutions, or foundations with public 
health initiatives.  These models are set up to defer the costs of early stage drug 
development to the public through i.e. NIH, while improving the academic drug 
discovery capabilities and the value gained from NIH funded research. 
 The pharmaceutical industry and academia have shared a rich history.  In the 
past, companies have been formed by commercializing new drugs developed by 
academic researchers.  One of the most well-known examples of this was 
Genentech, founded by Herbert Boyer of UCSF and venture capitalist Robert 
Swanson in 1976.32  More recently there is Vertex, Infinity, and H3 Biosciences all 
produced by Professor Stuart Schreiber and colleagues at Harvard University.  
Finally, there is a list of well-known drugs that have come out of academic 
institutions including pregabalin (LyricaTM; Silverman lab, Northwestern), 
emtricitabine (EmtrivaTM; Liotta lab, Emory) and premetrexed (AlimtaTM; Taylor lab, 
Princeton).33-35  
 These early cases have paved the way for official partnerships between 
Pharma and Academia and these collaborations continue to grow to this day.  As of 
2017 the Academic Drug Discovery Consortium reported 148 active university-led 
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drug discovery centers across the country.  This consortium also tracks partnerships 
between these centers and the pharmaceutical industry and some notable ones 
include Yale University (GSK, Gilead Sciences, Evotec AG), UCSF (Sanofi, 
Genentech, Bayer, Pfizer), Vanderbilt (Bristol-Myers Squibb, Astra Zeneca, GSK), 
University of Pennsylvania (Novartis, Astra Zeneca), Broad Institute of Harvard and 
MIT (Astra Zeneca), UC San Diego (Roche), Oxford University (Novo Nordisk, 
UCB), California Institute for Biomedical Research (Merck), Harvard University 
(UCB), and Johns Hopkins Brain Science Institute (Janssen Pharmaceuticals).  
Relying on public funding, it is critical for these academic institutions to have access 
to technology to reduce the costs of drug discovery as much as possible. 
1.4 Current State of Technology for Screening for Neurological Conditions 
New technology is being developed continuously to advance small molecule 
screening, improving efficiency, efficacy, and reducing costs.  High-density microtiter 
plates such as 96- and 384-well plates remain the gold standard for cell-based 
phenotypic screening; however these plates are still relatively low in throughput 
resulting in the need for large populations of cells and significant volumes of 
compounds and reagents.  Higher throughput plates such as 1536- and 3456-well 
plates have been designed, with the former starting to become more prominent, 
however these plates are marked by high evaporation and require expensive 
equipment for handling.  Increased focus has been placed on the use of 
microfluidics in screening in order to address these issues.  Microfluidic approaches 
for drug discovery can be divided into two major categories, array based systems 
and droplet based systems. 
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1.4.1 Array Based Microfluidic Systems 
Wlodkowic et al. published in 2009 the design of a polydimethylsiloxane 
(PDMS) array of micromechanical traps to hydrodynamically capture single 
nonadherent hematopoietic cells (Figure 1.3).  After being exposed to anti-cancer 
drugs, this study showed that ~300 trapped cells could be analyzed with real time 
fluorescent imaging just as effectively as traditional single cell analysis techniques 
such as a flow cytometry which requires a much larger cell population.  This major 
drawback to this device is that it is a continuous system and cannot test multiple 
compounds in parallel.36  
Dimov et al. published in 2011 the development of an integrated microfluidic 
array plate (iMAP) which is a gravity driven (pump and tube free), PDMS based, 
microfluidic culture device for the capture and analysis of discrete populations of 
cells (Figure 1.4).  This device can interrogate 64 separate populations with the 
capability of performing real-time Nucleic Acid Sequence Based Amplification 
(NASBA) and immunofluorescent (IF) analysis.  Each populations consists of 5-50 
cells however culture of these cells was done under constant perfusion.  The 
performance of this device was demonstrated with NASBA, IF, and a drug dose 
analysis using HeLa and MCF7 cells.37  
Wang et al. developed a microfluidic cell array with individually addressable 
chambers.  Fabricated out of PDMS, this chip featured 36 chambers arranged in a 6 
x 6 array and access to these chambers were controlled with pneumatic valves 
through an automated system (Figure 1.5).  Cells were loaded into the array via 
syringe pump into the six inlets identified in orange in Figure 1.5, and access to the 
15 
 
cell chambers was controlled by surrounding, water-filled channels (identified in blue 
in Figure 1.5) which would expand and contract to gas pressure controlled by 
solenoid valves.  To seed specific cell types into specific chambers, the cell 
suspension in the syringe pump would have to be changed while the valves for the 
target chamber were open and the surrounding chambers were closed.  The utility of 
the device was demonstrated by seeding two cell types, regular Chinese hamster 
ovary (CHO) cells and EGFP-expressing CHO cells, into specific chambers, and 
then treating specific chambers with specific fluorescent dyes.  The number of cells 
in each chamber ranged in the 100s and were cultured for 2 days.38  
In an effort to seed and culture multiple cell types in specific localized 
positions in an easier and more efficient way, Gao et al. created a microfluidic device 
which does so utilizing vacuum actuation (Figure 1.6).  Fabricated from PDMS, this 
device featured 256 culture channels divided into eight individually addressable 
regions and all branched from a central main channel.  In their proof of design study, 
four cell types were seeded including HuT 78, Ramos, PC-3, and C166-GFP cells 
and viability and cell proliferation were measured.  With cultures varying from 2-7 
days, viability ranged from 92-97% and each cell population was individually 
monitored for its response to apoptosis inducing compounds.39 
Screening multiple compounds in combination is also a concern in drug 
development in order to assess possible side effects.  In order to reduce equipment 
and reagent costs for in vitro drug combination screening, Kim et al. designed a 
programmable microfluidic cell culture array for the generation of drug 
concentrations and then combined them pairwise with cell populations for 
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observation (Figure 1.7).  Fabricated from two layers of PDMS, one for fluid 
exchange and one for pneumatic control, this device featured 64 individually 
addressable cell culture chambers connected to a set of upstream concentration 
channels where compounds are diluted and combined.  Using human prostate 
cancer PC3 cells, the device was demonstrated by inducing viability loss by 
introducing combinations of the chemotherapeutic drugs doxorubicin and 
mitoxantrone with TNF-alpha Related Apoptosis Inducing Ligand (TRAIL).  One of 
the unique attributes of this device is its ability to operate without continuous 
perfusion, however media changes were performed every three hours possibly 
leading to a lower effectiveness in the combination treatments when compared to 
the use of traditional 96-well plates.40 
In an interesting effort to encompass all the tools and resources necessary for 
a drug screen, Zhou et al. developed an automated nanoliter dispensing microfluidic 
liquid handler and accompanying micro-multiwell chip which reduces reagent 
consumption and expands cellular throughput (Figure 1.8).  Using standard soft 
lithography methods, the nanoliter liquid handling pipette chip was fabricated with 
four channels in parallel which dispense 50 to 500 nL with a coefficient of variation 
(CV) < 8% at 150 nL.  This device dispenses cells and fluids into a 96-well microchip 
consisting of 12 X 8 individual microwells, with each microwell holding a maximum 
volume of 500 nL.  In demonstrating the device ~350 nL were dispensed in each well 
resulting in 400-500 cells per well.  These cells were grown for over 48 hours with 
media replacement every 8 hours.  Altogether, the study showed that cells could be 
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seeded, transferred, passaged, transfected, stimulated by drugs, and observed in a 
screening assay.41 
To address the growing need to miniaturize screening assays while also 
making them affordable, easy to handle, and accurate, Du et al. described in 2013 a 
2-dimensional PDMS based microfluidic culture device to increase throughput for 
combination drug testing (Figure 1.9).  The system was designed around the 
sequential operation droplet array (SODA) technique, and featured a chip with an 
array of 342 circular micro-wells each 1.3 mm in diameter and 10 µm in depth.  
Using this chip and an automated stage and capillary system, 11-day old cell 
cultures were achieved in oil-covered 500 nL droplets with media changes every 24 
hours.  Each droplet supported 80-100 cells/well of A549 cells.  Using this 
technology, not only was cell viability comparable to 96 and 384-well plates, but drug 
consumption for each well was reduced by 2-3 orders of magnitude.42 
To create a large number of unique microenvironments for the growth and 
analysis of stem cells, Zhang et al. developed a superhydrophobic microwell array 
chip (SMARchip) (Figure 1.10).  Seeding and fluid exchange in the chip was 
facilitated by a robotic spotter.  The SMARchip was fabricated by micrografting a 
PDMS array to the superhydrophobic layer via contact printing.  The final SMARchip 
consisted of a 960-well array each with a 500 µm diameter and a 100 µm-thick 
superhydrophobic layer.  In order to prevent evaporation, the device was handled in 
a custom built glovebox and contained double Petri dishes with sterile water during 
culture.  In demonstrating the performance of the device BHK-21, HUVEC, and K562 
cells were cultured for 2-5 days while growth rate and viability were measured.  
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Additionally, the device’s screening capabilities were demonstrated by culturing 
Oct4-EGFP mouse induced pluripotent stem cells (iPSCs) for four days and 
individually delivery soluble factors while measuring their effects on pluripotency and 
proliferation.43 
Similarly, Popova created a droplet microfluidic array (DMA) with super 
hydrophilic and hydrophobic areas to eliminate the risk of cross-contamination 
between cell clusters when screening on cell microarrays (Figure 1.11).  The DMA 
was fabricated using a standard microscope slide upon which a layer of nanoporous 
poly(2-hydroxyethyl methacrylate-co-ethylene dimethacrylate) (HEMA-EDMA) film 
was placed.  This surface was then functionalized with one reaction to create 
superhydrophilic squared spots and another reaction to create superhydrophobic 
borders.  In all, three different arrays were created with 588, 2187, and 4563 spots of 
sizes 1000 µm, 500 µm, and 350 µm respectively.  In evaluating the device, HeLa, 
HEK293, and A549 cells were seeded and then morphologically observed.  
Additionally, the utility of the DMA in screening was first tested by reverse 
transfecting HEK293 cells and then individually treating HeLa cells with doxorubicin 
and quantifying its effect on the cells by calcein staining.44  
1.4.2 Droplet Based Microfluidic Systems 
In order to study microbial ecology, physiology, evolution, and adaptation to 
changing environments, Jakiela et al developed a droplet based microfluidic device 
to isolate populations of bacteria (Figure 1.12).  Composed of ten input and output 
channels, the device performs three functions: 1) formation of microdroplets 
containing cells, reagents, and grow factors; 2) cycles microdroplets for cell 
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incubation and monitoring; and 3) splits and fuses microdroplets to control the 
modulate the concentration of injected chemical factors.  Using the device 164 
microdroplet chemostats were produced and monitored. Chemostats are culture 
modules for bacteria, yeast, and algae which continuously replenish fluids to 
maintain volume and concentration of growth reagents for the optimal culture 
environment.  Microfluidics greatly reduces the cost of producing these chemostats, 
so in demonstrating the application of this device, the growth and response of E. Coli 
cells (~14,000 cells per droplet) was observed after being introduced to varying 
concentrations of tetracycline and chloramphenicol and the bacterial showed similar 
growth to that grown in a bulk environment.45 
In a demonstration of digital microfluidics (DMF), Bogojevic et al. developed 
the first DMF device to implement a parallel-scale cell-based assay (Figure 1.13).  
Using photolithography and etching this device was fabricated as two plates 
separated by a 140 µm space with patterned chromium electrodes on the bottom 
plate and a 50 nm Teflon-AF coating on either side of the inside surface.  The device 
has six 1.5 mm diameter assay zones in the central region with twelve adjacent 
reagent reservoirs. After plating HeLa cells at approximately 800 cells per assay 
zone and incubating overnight, a fluorogenic apoptosis assay for caspase-3 activity 
was performed since it is popular in anti-cancer drug discovery.  The results showed 
a 33-fold reduction in reagent consumption and lower detection limit and greater 
dynamic range than the same assay performed in a 96-well plate.46 
As seen from these examples, there are a wide variety of approaches in 
developing microfluidic platforms for drug screening.  While these devices are able 
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to interagate small cell populations with extremely low reagent volumes, they do 
suffer certain consequences, namely the ability to produce long term cultures.  
Except for the Du and Zhang devices, these platforms have not been proven to 
support cells for more than 48 hours, and all require frequent media changes.  There 
has yet to be a commercially popular device that combines the volume advantages 
of 384-well plates with the throughput advantages of microfluidics. 
1.5 Use of Human iPSC Derived Neurons in HTS 
1.5.1 History and Advantages of Human iPSCs 
With the increased focus of the pharmaceutical industry on treating 
neurological disorders, there is a greater need for accurate disease models.  With 
the discovery and development of human induced pluripotent stem cells (hiPSCs) a 
massive movement has been underway to realize the potential of this new 
technology in better understanding the pathology and mechanisms of neurological 
disorders as well as discovery of new drugs to treat them.  Although extensive 
efforts have been made, therapies have failed to come to fruition.  The reasons for 
this failure include the polymorphic nature and our lack of understanding of the 
disease pathogenesis, the failure of animal models to fully recapitulate all aspects of 
the disease including genetic - environmental interactions, and limited access to 
human cellular samples at different stages of maturation and disease progression. 
Animals have been used widely in the study of diseases and their 
mechanisms; however use of animal models in drug discovery has not led to 
successful therapies in the clinic.47  These failures may be in part due to genetic, 
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anatomical, and/or physiological differences between animal models and humans.  
In the case of rodents, which we diverged from 60 million years ago, there are 
significant genomic differences such as noncoding and regulatory RNA that play a 
major role in disease epigenetics.  Anatomically there are major differences as well, 
such as the difference in development of the prefrontal and temporal cortex of the 
rodent versus the human brain.  Also, rodent brains are lissencephalic and don’t 
contain certain types of neurons that exist in the human brain such as Von Economo 
neurons.48  Such differences affects neurogenesis and neuronal function, therefore 
neurons dissected from mice may not always have the same morphology as human 
neurons.  Finally, in terms of physiology, these genetic and anatomic differences 
effect neuronal function, and thus rodent neurons behave differently as well.  
Specifically, it has been shown that rodent neurons have different 
electrophysiological properties than human neurons.49  Taken together, these 
differences may explain part of the discrepancies between preclinical and clinical 
data. 
Given the threat of misinformation posed by animal models, new attention is 
being given to the use of human cells for drug screens.  However access to human 
brain tissue may be difficult to impossible to obtain.  Currently, human brain tissue 
can be extracted from live surgeries, or postmortem subjects.  For a variety of 
reasons however, these samples are not ideal for high-throughput screening.  First, 
similar to rodent neurons, they are post mitotic and there is a limited supply of 
tissue/cells that can be derived – not nearly enough needed for screens or repeated 
experiments.  Second, these neurons represent cells at a late stage of development 
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and therefore are not ideal for modeling neurodevelopment in early onset diseases.  
Furthermore, neurons derived from postmortem subjects or neurosurgeries eliminate 
the possibility of performing patient specific screens or establishing biobanks that 
represent the mosaic nature of many neurological and neuropsychiatric diseases. 
Given the limitations of these current models, human iPSCs make it possible 
to perform screens on human neurons from patients with specific genetic mutations 
caused by a known neurological disorder.  The discovery of these cells thus was a 
major breakthrough and even overcame the moral challenges of using embryonic 
stem cells (ESCs) which were already seeing limited use.  In 2006, Takahashi and 
Yamanaka discovered hiPSCs, for which they received the Nobel Prize.  In their 
landmark paper, they demonstrated that mouse fibroblasts could be reprogrammed 
into a pluripotent state similar to ESCs by introducing transcription factors in a 
retroviral-mediated process.  The four transcription factors used in this study were 
OCT3/4, SOX2, c-MYC, and KLF4.50  After induction, pluripotent stem cells can 
differentiate into any human cell, and within a year of these original studies, human 
iPSCs had been generated from a number of different tissue sources, fibroblasts 
and peripheral blood being the most common.51 
High-throughput screening using stem cell derived neurons was first 
demonstrated with ESCs.  McNeish et al. performed a screen of over 2 million 
compounds to identify a glutamate receptor potentiator to enhance cognitive ability.  
The primary screen was carried out using mouse ESC-derived neurons while the 
secondary screen to validate the leads was performed on human ESC-derived 
23 
 
neurons.  This campaign paved the way for eventual screens using hiPSC-derived 
neurons.52 
1.5.2 Current Use of hiPSC-derived Neurons 
Executing effective screens for neurological and neurodegenerative disorders 
partially depend on the types of neurons available.  Over the years various types of 
neurons have been derived from hiPSCs with motor, cortical, and dopaminergic 
neurons being the most developed and characterized.  Each of these types of 
neurons is produced from a different differentiation protocol, and these protocols 
have evolved over the years. 
In 2008 Eggan et al. first demonstrated motor neuron differentiation from 
human somatic cells.  Established from a previous study which produced MNs from 
mouse stem cells using a retinoic acid (RA) and sonic the hedgehog (SHH) for the 
neural patterning, Eggan’s group was able to mimic this same protocol in hESCs.53  
Shortly thereafter this method was adopted by Ebert to produce motor neurons from 
hiPSCs.  This was the first study to show a disease specific phenotype in 
differentiated motor neurons, and paved the way for future studies, however it 
resulted in an efficiency of less than 10% and required a 56-day differentiation time 
frame.54  Since then efficiencies and differentiation times have improved, but are still 
not ideal for large scale screening purposes. (Table 1.6)  
Similar to motor neurons, cortical neurons were first developed using ESCs.  
In 2009 Li et al. produced cortical glutamatergic cells from hESCs using RA in the 
absence of morphogens.55  Also during that time Eiraku et al. differentiated cortical 
neurons from hESCs using a three-dimensional quick aggregation culture (SFEBq) 
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method in 24 days.56  It was not until 2012 however that cortical neurons were 
differentiated from hiPSCs by Shi et al. in their landmark study.  In this elegant work, 
dual SMAD inhibition using Noggin and SB431542 was combined with retinoids to 
produce 95%efficiency; however differentiation time for mature neurons was 
between 60 to 90 days.  Although this is consistent with the time frame of 
neurogenesis in human development, it is not ideal for screening campaigns.  
Fortunately other protocols with shorter differentiation times have been produced 
since then, but efficiency has suffered at the cost of reducing time (Table 1.6). 
Dopaminergic (DA) neurons play a key role in regulating reflexive actions and 
is implicated in Parkinson’s disease (PD).  One of the first groups to differentiate 
hiPSCs into DA neurons was Chambers et al. in 2008.  Introducing the dual SMAD 
inhibition patterning technique using NOGGIN and SB435142 for the first time, this 
groundbreaking study produced DA neurons in 19 days with 82 percent efficiency.57 
 Having a selection of different types of neurons available from hiPSC 
differentiation is critical in carrying out screens for different neurological and 
neurodegenerative diseases, however screening with these cells is still in its infancy.  
Early screens have been carried out using dividing neuro progenitor cells (NPCs) as 
these cells are still scalable and homogenous52; 58.  However, NPCs do not have the 
full disease phenotype and thus reaction of mature neurons to compound treatment 
cannot be fully ascertained.  Of the instances listed in (Table 1.7) where iPSC-
derived neurons were used to model diseases in the past four years, in only a few 
cases were they actually used in screening campaigns. 
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In targeting Parkinson’s disease Scwab and Ebert created sensory neurons at 
20% efficiency after a 21 day differentiation period from patients carrying the LRRK2 
G2019S mutation.  In studying the morphology and function of theses neurons using 
imaging techniques they found the presence of large microtubule-containing neurite 
aggregations as well as altered calcium dynamics.  When treated with three LRRK2 
kinase inhibitors LRRK2-IN-1, GSK2578215A, AND CZC25146 they observed a 
significant, but partial rescue in morphology and a full rescue in calcium dynamics.  
These findings supported the idea that kinase activity is implicated in PD neuronal 
dysfunction.  It also showed minor line-to-line differences due to patient variability in 
the iPSCs used which is a partial hindrance to screening with iPSC-derived neurons.  
Furthermore, although a full screen was not executed, this study showed that small 
molecules could be tested on hiPSC-derived neurons and valuable information 
retrieved. 
 Probably the best demonstration of hiPSC-derived screening has been 
associated with FXS.  Two separate screens were published in 2015; however 
neither used fully mature neurons.  Using a high content assay Kaufmann et al. 
screened 50,000 compounds to see which ones upregulated FMRP production in 
neural precursor cells.  The study concluded with several compounds that produced 
a small but detectable increase in FMRP.  Moreover it showed the feasibility of 
plating iPSC-derived cells in high-density well plates.59   Kumari et al. used at 1536-
well plate format and screened 5,000 compounds on neural stem cells using a time-
resolved fluorescence resonance energy transfer (TR-FRET)-based assay to 
measure increases in FMRP.  TR-FRET is an assay format in which a donor 
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fluorophore, when excited by a light source, releases energy towards a nearby 
acceptor fluorophore which in turn emits a specific fluorescent wavelength which is 
detected.  Using this technique, this study concluded with six compounds that 
modestly increased FMRP production, however this work provided proof of principal 
for using TR-FRET in this format with patient iPSC-derived cells.60  
 In HD, there have been recent studies performed on hiPSC-derived neurons; 
however these studies have only used these neurons to validate compounds 
discovered in larger primary screens.  Kumar et al. created mesencephalic 
dopaminergic neurons in 26 days for a study to better elucidate the intracellular 
processes that regulate neuronal manganese (Mn) homeostasis.  Following a 
40,167 compound primary screen based on a fluorescence Mn measurement assay, 
9 compounds were selected for validation on the hiPSC-derived neurons and 
interestingly all nine showed varying activity at different stages of maturation of the 
neurons.  Such a study would not be possible in animal or postmortem models, thus 
this work demonstrated more accurately the possible use of these compounds to 
regulate Mn levels in humans.61 
 Recently another screen was performed targeting HD treatment.  Combining 
in vitro single molecule fluorescence spectroscopy, in silico molecular docking 
simulations, and in vivo fly and mouse HD models, 19,468 physical compounds were 
screened for inhibitors of abnormal interactions between mutant HTT and Ku70, a 
mutation repair protein.  Fifty-six hits were produced from this primary screen and 
three were tested on HD patient derived cortical neurons.  Using confocal 
microscopy and immunocytochemistry, it was concluded that these compounds 
27 
 
improved dendrite length and spine density, but did not reduce the number of 
inclusion body positive neurons present.  Taken together however, treating these 
neurons illustrated the therapeutic effectiveness of these compounds.62 
 1.5.3 Challenges of hiPSC-derived Neurons 
From the previous examples, it is clear that screening on hiPSC-derived 
neurons is still in its infancy, and has a long way to go before it is commonplace.  
There are significant reasons why screening with hiPSC-derived neurons has not 
accelerated, and these challenges must be overcome to unlock the true potential of 
this technology.  These challenges include biologic, logistic, and economic factors. 
 One of the major threats to screening with hiPSC-derived neurons is the 
possibility of the existence of genetic mutations separate from the disease as well as 
epigenetic memory from the somatic tissue of origin.  Historically, iPSCs have been 
generated via a lentiviral or retroviral reprogramming process, however these 
techniques can lead to mutations at the integration site, copy number variations, or 
abnormal karyotypes.63  These genetic aberrations could possibly lead to problems 
during differentiation and may affect the final disease phenotype. 
 New strategies using transgene-free techniques have been employed to 
minimize or eliminate the negative effects caused by the early reprograming 
methods.  Excisable factors have been developed including floxed lentiviral and 
transposon vectors, while non-integrating factors such as adenoviral, plasmids, 
Sendai viruses, mRNA transfections, recombinant proteins, RNA viruses, and 
miRNA viruses have also been developed.  Furthermore, small molecules such as 
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valproic acid, vitamin C, SB431542, PD0325901, thiazovinin, sodium butyrate, and 
forskolin have demonstrated improved reprogramming results when utilized.  
 Another genetic challenge for hiPSCs and their resulting neurons is the threat 
of retaining genetic information from the original somatic cells from which they were 
derived from.  In their paper in Nature, Kim et al. was one of the first to report that 
low-passage iPSCs harbor residual DNA methylation signatures characteristic of 
their somatic tissue of origin.  Furthermore, these residual signatures favored 
differentiation along lineages of the donor cell as opposed to alternate cell types.  
They also showed that this ‘epigenetic memory’ could be reset via serial 
reprogramming or by treatment of iPSCs with chromatin-modifying drugs.64  In a 
similar vein Liester et al. showed that somatic memory was independent of 
reprogramming techniques.65.  Increasing passage number and culture time 
however could possibly reduce these effects and make iPSCs behave more like 
ESCs.66; 67 
 Apart from the genetic concerns, another major challenge is having access to 
consistent iPSC lines.  Disease phenotypes should be the same among iPSC lines 
with the same gene mutations. This is true for lines derived from the same patient, or 
different patients even though they have a different genetic background.  However, 
this is not always the case, and environmental factors sometimes interfere.68; 69  In 
order to increase reliability and reproducibility large panels of well characterized 
iPSC lines from a wide cohort of patients representing the mosaic nature of most 
neuropsychiatric and neurodevelopmental diseases should be organized and 
properly maintained.  In this spirit, repositories such as the Coriell Institute for 
29 
 
Medical Research, the HD consortium, and the UK Biobank have been established.  
Furthermore, it is important for screening campaigns to use multiple iPSC lines to 
ensure that disease-specific cellular phenotypes are detected beyond this normal 
variability. 
 Having proper controls is also vital.  Historically, controls have consisted of 
iPSCs generated from age, gender, and race matched healthy donors, but these 
controls are not ideal because of the previously mentioned genetic variability across 
patients.  For these reasons, it is critical to be able to isogenically correct the 
disease mutations from the same patient lines as are used in the screen.70; 71  It is 
also critical to characterize those cells for precise disease related phenotypic 
readouts to ensure they are safe controls.  Fortunately there are a number of tools 
available today to create these isogenic lines including zinc finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENS)72, and clustered regularly 
interspaced short palindromic repeates-CRISPR-associated protein-9 nuclease 
(CRISPR-Cas9) and these tools are being increasingly used.73-75 
 The final major challenge of screening with hiPSC-derived neurons is the 
ability to generate large numbers of homogenous cells.  Currently it is possible 
expand neural progenitor cells, but these cells do not provide the rich phenotypic 
information of mature neurons, and are not ideal for modeling neurodegenerative 
diseases which are typically late-onset.  Protocols must be developed that improve 
differentiation efficiencies, however many of the measures taken already, such as 
non-integrating factors and small molecules, have increased developmental costs.  
Furthermore, in creating large populations of homogenous neurons, it is also 
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necessary to characterize these cells for their type, maturity, and functionality which 
require additional time. 
1.6 Summary 
 The pharmaceutical industry is consolidating, and in the process R&D is 
being outsourced to academic drug discovery centers which are supported by public 
research funding.  With this outsourced R&D, greater focus has been put on treating 
neurological disorders.  There are a number of well characterized neurological 
disorders that have no cure and only limited symptomatic treatments.  Failures of 
promising therapies in clinical trials have followed successful preclinical studies on 
non-human models.  For these reasons there is greater attention on the use of 
hiPSC-derived neurons for preclinical drug development.  This technology has yet to 
be used in a wide spread manner however because of the high costs associated 
with differentiation, characterization, and control preparation.  Furthermore, due to 
low efficiencies and long differentiation times, there is a demand for new technology 
to increase cellular throughput.  Development in microfluidics has increased to 
address this demand, however the main hindrance of this technology is its limited 
capacity for extended cell culture. 
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Figure 1.1. The number of new drugs approved by the US Food and Drug 
Administration (FDA) per billion US dollars (inflation-adjusted) spent on 
research and development (R&D) has halved roughly every 9 years.30  
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Figure 1.2.  Approvals of new chemical entities by the US FDA:  1940-2010.28  
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Figure 1.3.  Microfluidic live-cell array (array cytometer). (A) CAD schematic of 
the chip layout showing a triangular microculture chamber, containing the cell 
trapping array. (B and C) SEM images of the array of PDMS cell traps.36  
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Figure 1.4.  iMAP array (A) consists of 64 processing modules (B) that can 
perform 64 independent simultaneous integrated assays. The integrated 
function of each processing module can be flexibly selected by the user and 
depends entirely on the sequence and timing of the fluid inputs. The basic 
steps required for three different cell based assays are illustrated (A). This 
versatility allows the user to combine cell stimulation and gene and protein 
expression analysis on a single microfluidic platform. For statistical 
replication purposes each module consists of 8 parallel and equally 
distributed (C) processing chambers that contain a central trench structure 
(D). Each processing chamber can execute any sequence laboratory unit 
operations (E), gravity driven flow (E1), cell capture (E2) and reagent loading 
and mixing (E3).37  
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Figure 1.5.  (a) The schematic of the multilayer microfluidic cell array. The 
fluidic channels and chambers (in the fluidic layer) are shown in orange while 
the surrounding valves (in the control layer) are shown in blue. (b) The 
operation of a surrounding valve and the microfluidic culture chamber under 
its control. The channel depth is 18 µm in the fluidic layer and 25 µm in the 
control layer. The sample flows mainly through the chamber when the valve is 
open due to the higher flow resistance in the bypass channel. The sample 
flows through the bypass channel when the valve is closed. (For interpretation 
of the references to color in this figure legend, the reader is referred to the 
web version of the article.)38  
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Figure 1.6.  a) Overview of device design. b) A closeup of the culture wells. 
The main fluidic channel was 5.5 cm long and 300 μm wide, while side 
channels were 1 mm long and 150 μm wide. There were 128 repeat side 
channel units on each side of the main channel. The 256 culture channels 
were divided into 8 regions of 32 culture channels. 2 control channels were 
located above the side channels on each region (8 control channels total), on 
the neck and end of side channels, respectively. The control line on the end 
was used for vacuum actuation. The line on the neck was used as a debubbler 
to remove air in channels.39  
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Figure 1.7.  Schematic of the microfluidic array. (A) Different concentrations of 
drugs A and B are generated in the diffusive gradient mixer, and used, either 
sequentially or in combination, to perfuse cells cultured in downstream 
microchambers. The mixing operation for generating different drug 
combinations and the opening and closing of valves for perfusing cells in the 
microchambers are controlled through a LabVIEW interface. (B) Depiction of 
the range of concentrations that can be generated for sequential and 
simultaneous treatment using color dyes. In the left panel, yellow and blue 
color dye solutions (representing the minimum and maximum concentrations 
of one drug) are mixed to generate eight outlet concentrations (‘‘horizontal 
gradient’’ of colors between yellow and blue), and represent the gradient used 
in sequential exposure experiments. In the middle panel, yellow and red 
streams (representing the minimum and maximum concentrations of the 
second drug) are mixed together to generate a ‘‘vertical gradient’’ of colors 
between yellow and red. Merging the two color gradients (vertical direction 
concentration gradient: yellow to blue; horizontal direction concentration 
gradient: yellow to red) yields an array of pair-wise combinations, and 
represents the gradient used in simultaneous exposure experiments (right 
panel).40  
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Figure 1.8.  The microfluidic liquid handling system. (a) A microfluidic chip 
was aligned to the microwell chip horizontally and vertically using a 
microscope and a camera. Inset: a close view of the outlet of the microfluidic 
pipet chip. (b) A four-channel microfluidic liquid pipet chip. (c) Before and (d) 
after the microwell chip was filled with ∼350 nL of liquid sample in each well. 
Scale bars are 5 mm.41  
44 
 
 
Figure 1.9.  Fluorescence images of an on-chip array of 342 droplets with A549 
cells.42  
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Figure 1.10.  Superhydrophobic microwell array chip (SMARchip) and 
operation procedure. (A) Micrografting procedure for fabricating the 
SMARchip. (B) Photos and scanning electron micrographs of the SMARchip. 
The SMARchip consists of a microfabricated polydimethylsiloxane (PDMS) 
microwell array and a superhydrophobic polymer layer. (C) A droplet array of 
culture medium spontaneously forming in the microwells due to the repelling 
effect of the superhydrophobic layer on the aqueous solution. (D) Typical side-
views of the droplets in microwells before and after a sweep with a cell 
spreader. (E) Average volumes and standard deviations of droplets in 
microwells with a depth of 200 μm before and after a sweep. The volumes were 
calculated from the side-views of the microwells (n = 10). (F) Experimental 
procedures for cell seeding and medium exchange on the SMARchip.43  
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Figure 1.11.  Droplet-microarray (DMA) reverse cell screening platform. (a) 
Schematic representation of a DMA slide and a table showing the sizes of the 
superhydrophilic spots and corresponding superhydrophobic borders. (b) 
Photographs of droplet microarrays. Scale bar 1mm. (c) Schematic diagram of 
the workflow of reverse cell screening using a DMA platform.44  
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Figure 1.12.  a) Diagram of the layout of the microfluidic device. b) A sequence 
of micrographs illustrating the splitting of one microdroplet into a seed droplet 
and waste droplets with pre-programmed volumes. c) A sequence of 
micrographs illustrating the fusion of the seed droplet with fresh media to 
control the chemical composition and number of cells in a microdroplet.45  
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Figure 1.13.  DMF device used for multiplexed cell-based assays. a) Top-view 
schematic of full device bearing six assay zones. b) Top- and side-view 
schematics of one assay zone.46  
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Table 1.7. hiPSC-derived disease models  
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Chapter 2:  Neuronal Cell Culture Performance of Microraft Arrays 
2.1 Introduction 
 Currently 1536-well plates represent the most practical option for drug 
discovery researchers seeking the highest throughput for their cellular screening 
campaigns.  The throughput advantage of these plates however comes with a cost.  
Using such high-density plates requires expensive equipment.  Additionally, these 
plates suffer high rates of evaporation which threatens cell viability and physiology.  
In dealing with such issues, plates either must be sealed or cell growth must be 
limited to only a few days. 
 In 2016 Thorne et al used hESC-derived astrocytes to identify compounds 
that protect against oxidative stress.  Using 1,536-well plates 4,000 astrocytes were 
plated in each well, however these cells were only maintained for up to 72 hours with 
media changes every 24 hours.1  Similarly, in Dai et al., in testing a coating-free 
plating method for iPSC-derived neurons plated 3,000 cells per well in 1,536-well 
plates, but these cells were only maintained for 24 hours.2 
 To achieve longer cultures technical measures such as plate sealers must be 
implemented.  In a high-content screen on mouse retinal neurons to identify 
compounds that are neuroprotective and promote photoreceptor differentiation, 
Fuller et al. plated 1,000 cells per well in 1,536-well plates and incubated them for up 
to 21 days.  This extensive growth was achieved however using Breath-Easy gas-
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permeable membranes (Diversified Biotech) and MicroClime vapor barrier lids 
(LabCyte).3  
Microraft array technology represents a promising solution to the issues 
mentioned that have plagued other devices.  Microraft arrays are culture devices 
consisting of approximately 1600 releasable paramagnetic particles (Figure 2.1 A).  
In the array, these particles are arranged in an orthogonal grid separated by PDMS 
borders.  Cells are plated onto the device en masse, and each particle supports an 
individual subpopulation of cells for extended growth. 
The Microraft arrays were originally developed by the Allbritton group at the 
University of North Carolina at Chapel Hill.  Where this technology was originally 
developed for the isolation and sorting of specific cells from a heterogeneous 
population, this work explores the use of this technology for increasing throughput in 
neuron based drug screening.  The fabrication of these microraft arrays follows a 
standard soft lithography process.  Briefly, a photoresist master is created on a glass 
substrate upon which polydimethylsiloxane (PDMS) is poured and cast.  After curing, 
the PDMS is then dipcoated into a poly (styrene-co-acrylic acid) solution containing 
1 % wt./wt. γFe2O3 nanoparticles to form the individual Microraft particles.  After 
curing, this assembly is then attached to a polystyrene culture cassette using 
additional PDMS as adhesive.  The microraft array is currently being commercialized 
by Cell Microsystems, Inc. under the trademark CellRaftTM technology (U.S. patent 
#9,068,155 B2).  The current devise being commercialized contains square particles 
with a side length of 250 µm.  Throughout this dissertation, a modified array was 
used containing square particles with side lengths of 500 µm (Figure 2.1A).  Larger 
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particles were chosen for these studies for easier manual use of the microraft array 
as well as a flatter profile, which is more beneficial for imaging given the concavity of 
each particle. 
The microraft arrays were first described by Wang et al. in 2010 in “Lab on a 
Chip” as a device for single cell analysis.  It has been tested in sorting 
heterogeneous populations of H1299 cells as well as the successful sorting of 
AsPC-1-Luc cells and subsequent transplantation into nude mice for tumor growth 
analysis.4  More recently, this technology has been used to sort T-cells and Epstein 
Barr virus-infected lymphoblastoid cells.5; 6  This new microraft technology was 
designed to replace a previous array device which used photoresist for its micro 
elements and a focus laser to release them.7  The improved microraft array 
fabricated from poly (styrene-co-acrylic acid) polymer was shown to have extremely 
low auto fluorescence compared to the previously used photoresist materials.  
Furthermore in demonstrating the cell-culture functionality of the array, multiple cell 
types were cultured on the device.  HeLa cells were cultured for up to 8 days on the 
intact array and >99% of cells were located within the wells on individual microrafts 
20 minutes after plating and a single media wash.  In addition to HeLa cells, Es129 
embryonic stem cells were cultured for 50 h and pancreatic tumor cells from live 
donor were cultured for 23 days.  Furthermore, cell viability following release of the 
microrafts from the PDMS substrate was assessed by releasing microrafts with a 
single HeLa cell and then observing the cell division.  The results of these studies 
showed that 100% of the HeLa cells remained on the microraft surface, and after 
144 h, 95 ± 8.7% of the single cells had formed small colonies.8 
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Initial tests of the microraft array with neuron cultures were performed in the 
Taylor lab by Mark Niedringhaus.  The findings of these studies were published in 
Scientific Reports in 2015.  In this research H9 embryonic stem cell derived neurons 
were first cultured on the microrafts to demonstrate their potential in expanding 
throughput for screening with stem cells.  In the first set of experiments ESC-derived 
neurons were cultured for five days on the microrafts and neuronal markers MAP2 
and VGLUT1 were positively expressed and the FM dye release rate was measured 
showing normal synaptic activity.  In these experiments however, microrafts were 
released from the array and transferred to large volume well plates such as the 6 
and 12-well variety.  In another experiment, the cell viability of ESC-derived neurons 
was compared to those grown directly in 384-well plates.  After five days of growth, 
the microrafts showed a significantly lower percentage of dead cells, however again, 
the microrafts were not transferred to large volume plates as opposed to high 
density 384-well plates.9 
Typically 384-well plates support 5,000-20,000 neurons/well and 1,536-well 
plates support 1,000-5,000 neurons/well.  Given a 1MM neuron/array plating density 
and ~1,600 microrafts/array each microraft supports between 300-500 neurons.  
Thus when looking at the high-end of these ranges the microraft array technology 
proposes a 40-fold increase in cellular throughput compared to plating directly in 
384-well plates.  Furthermore, if 1x106 neurons were plated on 384-well plates at a 
density of 20,000 neurons/well, this would only facility the screening of 50 
compounds compared to the 1,600 compounds promised from the microrafts when 
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the entire array is released and each microraft is distributed into individual wells 
(Figure 2.1 B). 
Microraft arrays therefore have the unique advantage of being able to support 
fewer neurons than 1,536-well plates but still take advantage of the volume benefits 
of 384-well plates when transferred into their wells.  Here the cell culture utility of 
microraft array technology in conjunction with the 384-well plate is demonstrated 
with hippocampal rat neurons as well as human ESC-derived neurons.  The primary 
objective for these studies was to assess viability of these neurons following transfer 
from the microrafts and growth in multiwell plates. 
2.2 Materials and Methods 
2.2.1 Microraft arrays and well plates 
Microraft arrays were fabricated according to previously published methods8; 
10.  Briefly, soft lithography was used to make the poly(dimethylsiloxane) (PDMS) 
template containing an array of microwells (each well has width x length x height = 
500 µm x 500 µm x 200 µm, array size = 25.4 mm x 25.4 mm).  The PDMS template 
was then dip coated with a 20% polystyrene solution in gamma-butyrolactone (GBL) 
containing 4% iron oxide particles.  The arrays are then placed in a convection oven 
at 95C for 16 hours to evaporate GBL to create the microrafts. The array was glued 
to a polystyrene cassette to facilitate handling, and then surface treated with air 
plasma (Harrick Plasma) for 2 min. 
The 384-well microtiter plates used for this experiment were Small Volume, 
LoBase, Polystyrene, µClear, black, tissue-culture-treated, sterile (788092; Greiner 
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BioOne, Frickenhausen, Germany).  The 1536-well microtiter plates used for this 
experiment were LoBase, F-bottom, Polystyrene, µClear, black, tissue-culture-
treated, sterile (783092; Greiner BioOne, Frickenhausen, Germany). 
2.2.2 Rat neuron culture 
All animal procedures were carried out in accordance with the University of 
North Carolina at Chapel Hill Institutional Animal Care and Use Committee (IACUC).  
Dissociated hippocampal cultures were prepared at embryonic day 18 from Sprague 
Dawley rat embryos as previously described11 with some modifications.  Briefly, 
hippocampal tissue was dissected in dissociation media (DM) containing 82 mM 
Na2SO4, 30mM K2SO4, 5.8mM MgCl2, 0.25mM CaCl2, 1mM HEPES, 20mM 
Glucose and 0.001% Phenol red.  Equal volumes of TrypLE Express (Invitrogen) 
and DM were added to the tissue and incubated at 37°C for 8 min.  Tissue was then 
rinsed and gently triturated in Neurobasal media (NBM, Invitrogen) supplemented 
with 1x B27 (Invitrogen), 1x Antibiotic-antimycotic (Invitrogen), 1x Glutamax 
(Invitrogen).  Dissociated cells were then centrifuged (67xg) for 7 minutes at 4°C, 
and resuspended (12x106 neurons/mL) in NBM.  Prior to cell dissociation, the 
microraft array, 384-well plate, and the 1536-well plate were coated with poly-D-
lysine (80 µg/mL; high molecular weight – 500-550 kDa) at 37˚C overnight and then 
rinsed three times with PBS.  Neurons were then plated on each plate type at 
equivalent densities as shown below. 
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Initial Plating 
  
 
Area 
(mm2) Cells/well 
Density 
(cells/mm2) 
Microraft 0.25 500 2000 
384 2.66 5320 2000 
1536 2.34 4680 2000 
 
Neurons were maintained in NBM until 7 DIV at which time they were fixed 
and stained.  Microrafts were released from their array after 2 DIV.  We released and 
transferred the microrafts after 2 DIV because at this stage their processes are not 
long enough to extend over the PDMS borders between the microrafts while they are 
still embedded in the array.  Waiting longer to release and transfer microrafts may 
cause injury to the neurons through shearing of processes that have grown over the 
borders. 
2.2.3 Stem Cell Culture 
 The NIH-approved, human embryonic stem cell (ESC) line H9 (WA09) was 
obtained from WiCell Research Institute (Madison, WI).  H9 ESCs were maintained 
as undifferentiated colonies on growth factor reduced Matrigel (BD Biosciences) in 
mTeSR1 media (StemCell Technologies). Media was changed daily.  Cells were 
passaged every three days with 0.5 mM EDTA (340 mOs). 
 Differentiation was initiated with mTESR media supplemented with the SMAD 
inhibitors SB431542, LDN193189, and XAV939.  These factors were incubated from 
Day 0-7 while retinoic acid was added on day 6.  On day 7 embryo bodies were 
plated on laminin coated plates and switched to N2B27 differentiation media.  At day 
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24, neuroprogeniter cells were plated on poly-D-lysine coated microraft arrays 
containing N2B27 media supplemented with BDNF. 
2.2.4 Immunocytochemistry 
The cell viability assay was performed as described previously with minor 
changes12.  Briefly, cells were grown for 7 DIV and then stained with a solution 
containing Sytox Green Nucleic Acid Stain (1:1000; Life Technologies, Inc.) and 
DRAQ5 Fluorescent Probe (1:500; Thermo Scientific) in NBM for 5 minutes at room 
temperature to label dead/dying cell nuclei and all cell nuclei respectively.  Following 
staining, the cells were rinsed three times for two minutes each with PBS and then 
fixed for 30 minutes with 4% formaldehyde.  After fixation, cells were rinsed three 
times for two minutes each with PBS and finally placed in PBS before imaging. 
2.2.5 Microscopy 
Imaging was performed on an Andor XDi imaging system featuring a 
Yokogawa spinning disk confocal unit and an Olympus IX81-ZDC2 inverted 
microscope with a motorized stage by Ludl as described previously 13.  Montages 
were taken of each plate type with a 20X objective and stacks ranging from 10 – 20 
slices each spaced 0.85 µm (z-distance) apart.  Dead cells stained by Sytox were 
captured using a 488 nm laser excitation and a 525-30nm single band fluorescence 
filter (Semrock Brightline), while the cell nuclei representing all cells were captured 
using a 640 nm laser excitation and a 637-60nm single band fluorescence filter 
(Semrock Brightline).   
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2.2.6 Image processing and analysis 
After acquisition, all images were analyzed with ImageJ as described 
previously 12. Briefly, images were imported using the Bio-formats plugin, slices were 
summed using maximum intensity projection, and then converted to 8-bit. The 
projected images were thresholded and the number of stained nuclei were counted 
within a 300 µm diameter region of interest in the center of the rafts using the 
‘Analyze Particles’ command. 
2.2.7 Statistics 
Statistical analysis was performed using GraphPad Prism 6 software.  
Percent dead was plotted as mean ± SEM.  Statistical significance for the Viability 
vs. Well Plate experiment was tested with a one-way ANOVA using a Kruskal-Wallis 
test.  Significance for the Viability vs. Cell Density and the viability of hESC-derived 
neuron experiments were tested with an ordinary one-way ANOVA using a Tukey’s 
test.  Significance with p-values < 0.001 are indicated with asterisks. 
2.3 Results and Discussion 
2.3.1 Rat Neuron Cell Culture 
The objective of this study was to establish the process of culturing neurons 
on microraft arrays.  The primary metric here was cell viability, but cell density and 
neurite outgrowth were also observed.  Since 384 and 1536-well plates are 
commonly used in screening campaigns, culturing on microraft arrays was 
compared to these traditional plate types.  After plating neurons on each substrate at 
equivalent densities of 2000 cells/mm2 they were maintained for 7 DIV, and then 
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fixed and stained.  To measure viability the cells were stained with Sytox (dead cells) 
and DRAQ 5 (all cells) and the viability was calculated as the ratio of Sytox positive 
cells to DRAQ 5 positive cells.  DRAQ 5 was used in this study because the natural 
fluorescence of the microrafts interferes with Hoechst, DAPI, and other nuclear dyes 
in the blue wavelength range. 
Although not statistically significant, the results showed the microrafts had a 
slightly better viability of 51% compared to 41% for the 384-well plate and 32% for 
the 1536-well plate (Figure 2.2A).  In addition the final plating density was quantified 
to show the level of cell adhesion.  This data showed that the microrafts had the 
largest final cell density with a mean of 1149 cells/mm2 compared to 700 and 833 
cells/mm2 for the 384-well and 1536-well plates respectively (Figure 2.2B) 
Once it was determined that the microrafts supported healthy neuron cultures, 
it was then necessary to determine the minimum total amount of cells to plate on the  
microrafts for a healthy culture.  Since the goal in using the microraft arrays is to 
maximize throughput, it’s important to minimize the amount of neurons on each 
microraft in order to do so.  For these reasons cell densities of 1x106, 1x105, and 
1x104 cells/array were plated on three separate arrays, maintained for 8 DIV and 
then fixed and stained for the same viability measurements.  Here it was found that 
1x106 cells/array performed the best with 29% cell viability compared to 9% for 
1x105 cells/array and 100% for 1x104 cells/array (Figure 2.3).  Together these 
results indicate that microraft arrays when plated with approximately 1 million cells 
produce healthier cultures than traditional multiwell plates used in screening. 
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2.3.2 hESC-Derived Neuron Cell Culture 
Following the successful culturing of rat neurons, human embryonic stem cell 
(hESC) – derived neurons were tested on the microrafts.  For these experiments the 
H9 ESC line was used and were differentiated as described in the Methods section. 
After optimizing the microraft array sterilization method, plating density, and 
the frequency of media changes, 500 K neuro-progenitor cells were plated on poly-
L-ornithine with laminin coated Cellrafft arrays.  The microrafts were released after 1 
DIV and transferred to a 12-well plate for further growth.  In a previous experiment 
hESC-derived neurons did not survive past ten days, so after 8 DIV the cells were 
fixed and stained.  The cells were observed daily and appeared healthy before and 
after transfer to the 12-well plate showing extended processes uniform dispersion 
(Figure 2.4C and D).  Using DRAQ5 nuclear dye, and SYTOX green to label the 
dead cells (Figure 2.4A and B), a viability assay was performed showing 47% cell 
viability which was consistent with the rodent neurons (Figure 2.4E). 
2.4 Conclusions 
Neurons are considered more delicate than most cell types.  Neurons cannot 
grow in single cell isolation because their growth depends on network 
communication, thus a certain cell density is required for healthy neuron cultures.  
This study concluded that neuron cultures on microrafts were somewhat superior to 
traditional well plates in terms of viability and final cell density.  In regards to viability, 
the three probable reasons why the microrafts outperform traditional multiwell plates 
is related to nutrient concentration in the media, change in pH, and oxygen 
exchange.  
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The cell rafts support on average 300 cells whereas 384-well plates and 
1536-well plates require between 5-20,000 cells per well and 1 – 10,000 cells per 
well respectively.  When taking the ratio of these cell densities to the volume of the 
wells, there is large proportion of nutrients per cell for the Cell rafts.  Thus, the 
significant increase in throughput for the same volume of media leads to cells with 
an adequate amount of nutritional resources. 
Another reason for improved cell culture with the microrafts is the change in 
pH.  Since the culture medium controls the pH of the culture and buffers the cells 
from changes in pH, as the media is consumed by the cells and as it evaporates, 
this pH change causes cell death.  Since the surface area of each well of 384-well 
plates is larger than 1536-well plates, the evaporation rate is larger, however since 
the volume of each well in 1536-well plates are approximately 1 2⁄  to 
1
12⁄  that of 
384-well plates, the changes in pH are much more significant.  Therefore we find 
that viability is worse in the 1536-well plates than the 384-well plates, and 384-well 
plates containing microrafts perform even better because they consume less media, 
keeping the pH stable. 
The last reason for higher viability is associated with oxygen exchange.  This 
phenomenon is also associated with the surface to volume ratio since vessels with 
small depths and large surface areas have high rates of oxygen diffusion.  In terms 
of surface to depth ratio the 1536-well plates have a factor of 0.578 versus 1.55 for 
384-well plates.  Therefore, the 1536-well plates have reduced oxygen exchange 
leading to lower cell viability.  Since microrafts have an approximate height of 150 
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µm, cells cultured on these particles are closer to the surface when placed in 384-
well plates leading to better viability than culturing directly in the 384-well plates. 
In addition to viability, a higher final cell density for Neurons plated on 
microrafts was observed compared to 384 and 1536-well plates.  Final cell density is 
important to understanding how well neurons are attaching to the surface.  It was 
observed that neurons plated on microrafts had a final plating density closest to the 
initial density.  Therefore it can be concluded from these results that not only are 
neurons adhering well to the microrafts, but they also remain adherent during the 
process of release and transfer to 384-well plates which was seen nicely in the 
hESC-derived cultures.  For neurons plated directly into 384-well or 1536-well 
plates, it’s postulated that these cells more often either adhere to the sides of the 
well, or do not adhere at all. 
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2.5 Tables & Figures 
 
Figure 2.1.  Microraft array design schematics (A) Image and design details of 
microraft array. (B) Throughput potential of microraft array  
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Figure 2.2.  Cell culture performance of microrafts with rat neurons (A) Cell 
viability versus culture plate type. (B) Final plating density versus culture plate 
type.  
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Figure 2.3.  Neuronal cell viability versus cell density using microrafts  
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Figure 2.4.  Human ESC-derived neurons grown on microrafts. (A) DRAQ 5 
nuclear marker. (B) SYTOX Green dead cell marker. (C) MAP2 microtubule 
neuronal dendritic marker. (D) Merged channels. (E) Mean cell viability.  
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Chapter 3:  Transfer of Microrafts 
3.1 Introduction 
Transport and manipulation on the cellular-scale is very important for 
biological research.  Cell separation, sorting, and single cell analysis have been of 
interest to biologist for decades, and achieving these tasks requires manipulation on 
the micron-scale.  Currently optical and acoustic techniques represent the most 
widely used methods for such manipulations. 
Historically, the first of these two techniques to be implemented was the 
optical approach, or better known as “optical tweezers”.  This technique was first 
demonstrated by Ashkin et al. in 1986.  In this work, he demonstrated the trapping of 
microparticals using a single tightly focused laser beam.1; 2  Even before using a 
single beam, Ashkin’s group demonstrated dual beam trapping, levitation of particles 
against gravity in both vacuum and air, and the movement of particles through 
liquid.3; 4  These techniques are still widely used today with little modification. 
In more recent years, there have been new developments in acoustic 
methods.  In 2010 Courtney et al. demonstrated a method of trapping and 
manipulating micron-scaled particles in liquid using ultra-sound.  In this method, 
spatially controlled standing waves are created with opposing piezoelectric 
transducers at either end of a liquid filled cavity.  Using the transducers to control the 
phase difference between the counter-propagating traveling waves, 5 µm-radius 
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polystyrene spheres were trapped and moved in one direction at 0.14 mm 
increments.5  
For the manipulation of particles in two directions, in 2012 Ding et al. 
developed a method to use acoustic standing surface waves to move and 
manipulate microparticles, cells, and microorganisms.  With a single layer 
microfluidic chip featuring four opposing chirped interdigital transducers in a square 
layout, 10 µm-sized polystyrene beads were transported in an arbitrary path in two 
dimensions.  Additional, demonstrating its biocompatibility Hela cells and C. elegans 
were maneuvered, and no significant damage was found in cell viability or 
proliferation.6 
All of these methods, although very powerful, only transport particles on a 
single platform.  In this work, the concept of transferring particles between platforms 
is addressed.  Here methods were tested including standard fluidic pipetting as well 
as a novel magnetic wand to transfer microrafts from their original array to a 384-
well plate.  The primary objective in this study was to create a solution for 
transferring microrafts in a manual fashion to avoid the costly fluid handling 
infrastructure of commercial drug discovery laboratories. 
3.2 Materials and Methods 
3.2.1 Design and Analysis 
3D solid modeling of the magnetic wand was created using SolidWorks 2012 
(Dassault Systems).  Detailed drawings of the magnetic wand were created in 
AutoCAD 2012 – Student Version (Autodesk).  Finite element analysis was 
79 
 
performed using COMSOL Multiphysics version 4.3 (COMSOL Inc.).  All finite 
element models were created axial symmetrically with a relative permeability of 
neodymium of 1.05 and a remenent flux density of 1.48T which is characteristic of a 
52 MGOe neodymium magnet.  A “physics controlled” extra fine mesh was used in 
all models. 
3.2.2 Magnetic Wand Materials 
For the design and testing of the magnetic wand 1/8” x 3/8” neodymium 
cylinder magnets grades N42 and N52 (D24 and D24-N52, K&J Magnetics, Inc.) 
were used as well as 1/8” x 1/4”  neodymium cylinder magnets grades N42 and N52 
(D26 and D26-N52, K&J Magnetics, Inc.).  For the probe and magnet shielding 
material Hy Mu 80 (ASTM A-753 Alloy 4) (Scientific Alloys Inc.) was used.  The 
probe used to attract the microrafts which was housed inside of the shield was 
fabricated from annealed “soft” iron. 
3.2.3 Fabrication of Magnetic Wand 
The magnetic wand probe and shield were fabricated with traditional 
machining techniques. 
3.2.4 Microraft Array Fabrication 
Microraft arrays were fabricated according to previously published methods7; 
8.  Briefly, soft lithography was used to make the poly(dimethylsiloxane) (PDMS) 
template containing an array of microwells (each well has width x length x height = 
500 µm x 500 µm x 200 µm, array size = 25.4 mm x 25.4 mm).  The PDMS template 
was then dip coated with a 20% polystyrene solution in gamma-butyrolactone (GBL) 
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containing 4% iron oxide particles.  The arrays are then placed in a convection oven 
at 95C for 16 hours to evaporate GBL to create the microrafts. The array was glued 
to a polystyrene cassette to facilitate handling, and then surface treated with air 
plasma (Harrick Plasma) for 2 min. 
3.2.5 Fluid Handling Materials 
Transfer of microrafts to 96-well plates was tested using a Thermo Scientific 
Multidrop Combi with the standard tube dispensing cassette (Cat # 24072670).  The 
microrafts were suspended in PBS with 0.1% Triton X and the droplet size was 
specified at 50 µL. 
Transfer of microrafts to 384-well plates was tested using a standard sixteen 
channel pipette manufactured by Eppendorf. 
3.3 Results and Discussion 
3.3.1 Design and Fabrication of Magnetic Wand 
There are two main approaches to picking up and transferring microrafts to 
multiwell plates– magnetic and fluidic.  The objective of the magnetic approach is to 
exploit the magnetic characteristics of the microrafts, picking up individual ones 
amongst a pool.  In order to achieve this, the magnet must be shielded such that it 
only attracts a single raft.  One of the major challenges with this approach is locating 
a magnet on the scale of the microraft which is 0.25 mm2.  There are Neodymium 
magnets you can purchase with diameters as small as 0.3 mm, however these 
magnets are very brittle and don’t produce fields strong enough to hold single rafts 
throughout the transfer process.  The ideal situation calls for a magnet that is big 
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enough and strong enough to attract and hold a single raft, but not so large that it 
attracts multiple rafts within the pool. 
To achieve this goal, the technique of channeling the magnetic field through a 
ferromagnetic material such as iron can be used to focus and direct the magnetic 
field to a small point thus attracting a single microraft at the tip.  This technique 
however still requires shielding of the magnet and probe to block the magnetic field 
from attracting additional microrafts to the sides.  This technique also requires 
attaching and separating the magnet from the channeling probe to attach and then 
release the microraft.  With these specifications in mind, a magnetic wand was 
designed based off of a standard push-button ball point pen (Figure 3.1A).  Tooling 
files were created in SolidWorks for 3D printing of all the components except for the 
magnet, shield, and probe (Figure 3.1B-D). 
The microraft must release from the probe tip when the magnet is separated 
from the probe, so the most desirable material for the probe is one with a low 
magnetic remanence.  Soft (annealed) iron, which is commonly used in electric 
motor cores, was used for these purposes because it has a narrow magnetic 
hysteresis loop with a coercivity (Hc) on the order of 80 A/m.  For the shielding, a 
material was needed that would block microrafts from being attracted to both the 
magnet and sides of the probe.  Since magnetic fields can only be channeled and 
not blocked, the material chosen would have to have a high magnetic permeability in 
order to achieve this goal.  Hy Mu 80 (ASTM A-753 Alloy 4) was chosen because it 
has a maximum relative permeability (µr) of 200,000. 
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After completing the design, the primary components for the magnetic wand 
including the probe and shield were fabricated.  These parts were fabricated using 
standard machining techniques.  The decision was made to forgo fabrication of the 
other components of the wand until the testing was concluded on the primary 
components. 
3.3.2 Analysis of the Magnetic Wand 
Finite element analysis was used throughout the design process to shape and 
define certain components as well as model their behavior.  The probe was modeled 
first in order to ascertain the appropriate length.  The objective in designing this 
component was to create a probe tip (probe + shielding) narrow enough to fit inside 
an individual well of a 384-well plate (Ø≈3.3 mm) to release the microraft, but long 
enough to maximize handling and decrease the transfer time.  The probe was 
modeled and analyzed in three different lengths, 1 cm, 1.5 cm, and 2 cm – all with a 
1 mm diameter.  The results of this analysis showed that the peak magnetic field 
strength decreases as the probe length increases (Figure 3.2).  Although a 2 cm 
probe would still be strong enough to attract a microraft, the 1.5 cm probe was 
chosen because a 2 cm probe would be almost impossible to machine with a 1 mm 
diameter. 
After finalizing the length of the probe, it was necessary to determine the 
proper angle in which the tip narrowed to its desired point (Figure 3.3).  The tip was 
designed to taper from a diameter of 1 mm to 0.25 mm.  The final diameter of 0.25 
mm was chosen because each microraft has a width of 0.5 mm and this will reduce 
the chance of attracting multiple microrafts.  The angle with which the tip tapers is 
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important however because the magnetic field emanates from the surface of the 
probe at 90 degree angles, thus in order to block the field effectively with the 
shielding the objective is to maximize the amount of field that id blocked by the 
shield.  Modeling various taper lengths revealed that longer lengths (more acute 
angles) provided higher magnetic field strengths along the axis of the probe and 
were more effective at blocking unwanted fields emitting perpendicular to the probe 
face (Figure 3.3). 
With the length of the probe and taper angle of the tip, it was also necessary 
to determine the minimum separation distance between the probe and the magnet 
necessary to release the microraft.  When separated, magnetic forces still transmit 
through the probe, thus a model was created to analyze the distance required for 
this force to reduce to a level insufficient to hold the microraft.  This distance was 
then incorporated into the design as the magnet retraction and intersection operates 
with a push-button spring mechanism.  After analyzing separation distances from 0 
mm to 12 mm, it was determined that at 10 mm or more, the field strength along the 
axis of the probe was 0.0044 T (Figure 3.4A-B) which is two orders of magnitude 
less than a common bar magnet and nearly as low as the Earth’s magnetic field 
which used as a near zero benchmark. 
3.3.3 Testing of the Magnetic Wand 
After completing the analysis and design, the probe and shield were 
fabricated for empirical testing.  Using an Olympus MVX10 macro-view microscope, 
the probe dimensions were validated following fabrication.  Three probes were 
fabricated and all were well within the range of the design specifications (Figure 
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3.5A-B).  The wand and shield were then adjoined using epoxy and the tip was 
polished flat (Figure 3.6A-B). 
In order to test the magnetic wand, a variety of magnets and magnet 
combinations were used.  In this test, the fabricated components were handled in 
the same fashion as the proposed wand, i.e. the probe-shield combination was 
placed into a microraft array with a pool of released microrafts, a microraft was 
retrieved from the pool and transported over to a 384-well plate where it was 
released by separating the magnet from the probe.  Four different magnets were 
used, D24, D24-N52, D26, and D26-N52 (K&J Magnetics).  Initially these magnets 
were tested each by themselves, but none of them were effective at attracting the 
microrafts, so combinations of two and three magnets were used.  Of the two 
magnet combinations, the D24+D24 and the D26-N52+D24 combinations 
transferred 1 microraft on average however the D24+D24 combination had more 
non-zero (transferring at least one microraft) transfers than the D26-N52+D24 
combination making it slightly more efficient (Figure 3.7A-B).  For the three magnet 
combinations the combination with the highest amount of non-zero transfers while 
also averaging 1 microraft was the D26+D26-N52+D26-N52 (Figure 3.8A-B). 
3.3.4 Fluidic Approach 
After testing the magnetic approach to transferring the microrafts two fluid 
based approaches were tested – using an established fluid handling machine and a 
multichannel pipette.  The fluid handling machine used was a Thermo Scientific 
Multidrop Combi Reagent Dispensor.  This instrument withdraws fluids from a single 
source and dispenses it into multiwell plates for high throughput plate preparation 
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and replication.  The Multidrop Combi is combatable to multiwell plates with 6 to 
1536 wells and has a dispense range from 0.5 to 2500 µL.  In testing this device the 
standard tube dispensing cassette was used which has an inner diameter of 0.5 mm.  
This is the same size as the microrafts, but this is the largest cassette available, so 
the test was carried out anyway.  In this experiment, a 50 µL setting was used to 
dispense a sample consisting of 64 rafts/mL into a 96 well plate.  During this 
process, microrafts were sucked out of the sample holder (50 mL Falcon tube) and 
through the dispensing cassette tubes, but the Cell rafts clogged at the tips of the 
cassette head.  Furthermore, in observing the cassette tubes, there were clumps of 
variable sizes and at variable frequencies throughout the tubes.  At the tips, the 
clumps ranged in sizes with some tips fully clogged, but others completely empty. 
With the failure of the Multidrop Combi Reagent Dispensor, attention was turned 
toward a traditional multichannel pipette.  In using this tool, microrafts are first 
released from their array, transferred to a pipette trough using a single channel 1 mL 
pipette, and then transferred to a 384-well plate with a 16-channel pipette.  In testing 
this method a range of volumes were used from 50 µL to 5 µL and the number of 
microrafts were counted per channel for each of the sixteen channels.  Of these 
volumes, 30 µL and 10 µL dispenses showed the least variability among channels 
(Figure 3.9) however 30 µL dispenses was seen as most optimal because for the 
same number of occurrences of single raft transfers, 21% on average, the 30 µL 
dispense had a lower number of empty wells than the 10 µL dispense at 27% 
compared to 35% respectively (Figure 3.10). 
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3.4 Conclusions 
There are few methods for physically transporting individual micron-size 
particles.  Here two methods were presented including magnetic and fluidic.  In the 
magnetic approaches a magnetic wand was successfully designed, analyzed, and 
fabricated to specifications.  Finite element analysis illustrated that a magnetic field 
could be channeled through a ferromagnetic material and the numerical trends 
associated with these fields when dimensional changes are made to the form of 
these materials.  Additionally, analysis also illustrated that the magnetic field could 
be focused in a single direction through the use of blocking materials which filter 
unwanted field lines.  These principles and phenomena were demonstrated through 
empirical testing of the fabricated probe and shield.  It was clear from these tests 
that it was possible to attract and transfer fewer than four microrafts and in some 
cases single microrafts although not as frequently as hoped and planned.  One of 
the main reasons for the poor performance of this device was presence of adherent 
forces created by fluid capillary action, i.e. the microraft remains adhered to the 
wand after the magnet is separated due to fluid tensile forces.  Unfortunately this 
phenomenon could not be adequately accounted for during the analysis phase of the 
design and was thus unanticipated. 
In turning to the fluidic approaches for transferring the microrafts, it was clear 
after testing that the Thermo Scientific Multidrop Combi was not going to work.  Even 
if the manufacturer produced a head with tips large enough for the microrafts to pass 
through, there was too much variability among the channels – with some tips 
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containing as many as ten microrafts clogged in it.  Furthermore, the along each 
tube were clumps of microrafts of varying sizes at various spaces. 
The concept of using a multichannel pipette to transfer the microrafts was a 
natural one.  This is a well-established tool in biology and has already been used 
extensively for micro-sized particles such as microbeads.  Furthermore it is manually 
operated and doesn’t require expensive automated machines.  Although this tool is 
variable among separate channels, this was expected, and in the use of this tool to 
transfer microrafts it was found to be effective overall.  In all instances, the pipette 
transferred on average less than five microrafts which is adequate in demonstrating 
the advantages in throughput this technology promises.  Taken together, this data 
illustrates that microrafts can be transported and manipulated manually by both 
magnetic and fluidic means with the best results achieved with the use of a 
multichannel pipette and low dispensing volumes. 
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3.5 Tables & Figures 
 
 
Figure 3.1.  Magnetic wand detailed drawings and 3D assembly. (A) Detailed 
cross-sectional profile (B) Probe and magnetic shield assembly. (C) Rear 
mechanical assembly for magnet engagement and disengagement. (D) Full 3D 
part assembly. Units are in centimeters.  
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Figure 3.2.  Finite element analysis of probe length.  Magnetic field 
(ampere/meter) is measured at the probe tip, and the arc length is measured 
perpendicular from the probe centerline.  
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Figure 3.3.  Finite element analysis of the probe tip.  Magnetic field 
(ampere/meter) is measured at the probe tip, and the arc length is measured 
perpendicular from the probe centerline.  
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Figure 3.4.  Finite element analysis of magnet probe-probe interaction. (A) 
Magnetic field (ampere/meter) from probe tip measured at multiple separation 
distances. (B) Computational model layout. (C) Model of probe with magnetic 
shielding.  Magnetic field lines are in yellow.  
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Figure 3.5.  Fabricated probe tip verification. (A) Comparison of three separate 
probes for accuracy. (B) Detailed drawing of probe with specified dimensions. 
Units are in millimeters.  
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Figure 3.6.  Magnetic probe encased with Hy-Mu80 magnetic shield. (A) 
Focused image shows tip of probe at center of magnetic shield. (B) Profile of 
probe-shield assembly.  
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Figure 3.7.  Magnetic wand performance testing with 2-magnet combinations. 
(A) Mean (rounded to whole number) number of microrafts lifted and 
transferred to a 384-well plate for each magnet permutation. (B) The number of 
times a microraft was transferred out of six attempts.  
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Figure 3.8.  Magnetic wand performance testing with 3-magnet combinations. 
(A) Mean (rounded to whole number) number of microrafts lifted and 
transferred to a 384-well plate for each magnet permutation. (B) The number of 
times a microraft was transferred out of six attempts.  
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Figure 3.9.  Microraft transfer performance with a sixteen-channel pipette at 
various draw/dispense volumes.  
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Figure 3.10.  Success rate for each number of microrafts transferred using a 
sixteen-channel pipette at various draw/dispense volumes.  
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1Chapter 4:  Magnetic Centering of Microraft in 384-Well Microtiter Plates 
4.1 Introduction 
Neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and 
autism affect millions of people worldwide.  However, most of the drugs available for 
these diseases are ineffective.  With the increased prevalence of phenotypic 
screening, new opportunities exist to discover both new targets and new drugs to 
treat these diseases.  Of the 28 new small-molecule entities (NMEs) approved by 
the FDA between 1999 and 2008, seven were developed from phenotypic screens 
based on the central nervous system (CNS).2 
The typical cost of a high throughput screening (HTS) campaign is estimated 
to be ~$1.00 per well or $500,000 for a screen of a half a million compounds.3 These 
costs however are greatly increased for screens using primary cells because of the 
high cost of raising and sacrificing animals to harvest tissue.  For neurons 
specifically, an even greater cost is incurred because of the post mitotic nature of 
these cells and the density with which they must be plated.  Plating densities vary 
depending on the type of assay performed, but typically screens use between 5,000 
– 20,000 neurons per well for proper growth and maturation4; 5, 6.  In a high content 
screen using primary neurons to identify compounds that promote neurite growth, Al-
                                               
1
 This chapter previously appeared as an article in the Journal of Biomolecular Screening.  The 
original citation is as follows: 
1. Gordon KR, Wang YL, Allbritton NL, Taylor AM. 2015. Magnetic alignment of microelements 
containing cultured neuronal networks for high-throughput screening. Journal of Biomolecular 
Screening. 20(9):1091-1100. 
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Ali et al. used 1,000 cells per well in 96 well plates; however, these cells were fixed 
and imaged after 48 hours.4. For assays requiring functional neuronal networks, 
higher densities and longer culturing periods are required7.  Thus due to the high 
costs and the large number of neurons required, there is an unmet need to develop 
higher throughput methods for neuronal screens.  Plating neurons in 1,536 well 
microtiter plates would increase throughput, but this approach is hindered by 
evaporation issues and difficulty seeding cells at the bottom of the wells. 
As highlighted in a recent review by Moraes, novel microfluidic and 
microengineered systems are quickly coming online to address the pitfalls that exist 
in modern screening methods8.  Along these lines, we previously reported the use of 
‘microraft’ array technology for screening (Fig. 1A,B). Using this technology we 
demonstrated the ability to increase the number of samples per unit cells > 30-fold9. 
Further, we successfully demonstrated the use of these microrafts in a previously 
established drug screening assay developed for Angelman’s syndrome using 
embryonic cortical neurons from Ube-3a-YFP transgenic mice5; 9. These arrays 
contain 1,600 polystyrene microelements (each termed microraft) doped with 
paramagnetic nanoparticles and arranged in an array on a polydimethylsiloxane 
(PDMS) membrane (25.4 mm x 25.4 mm).  Each microraft measures 500 x 500 x 
200 µm and serves as a surface suitable for culturing cells10; 11.  Cells are cultured 
en masse on the array and then microrafts are detached from the PDMS membrane 
and transferred either magnetically or via pipette to microtiter plates. 
One foreseeable application of this technology to screening is in the area of 
high-content screening.  High content screening is the simultaneous extraction of 
101 
 
data from multiple cellular parameters from many cells  usually using high-content 
imaging systems12.  High content imaging systems use automated platforms, plate 
and fluid handlers, and special software beyond that of regular microscopes, 
designed specifically for high density microtiter plates.  Unlike plate readers, high-
content imagers provide morphological and spatial information about the cells being 
screened13.  This information is vital in screens for diseases such as Alzheimer’s and 
fragile X syndrome where it is beneficial to observe synapse morphology and 
function. However, a major caveat to these systems is that in their automated 
processes, the objectives are usually positioned at the center of the wells by default 
as they traverse through the plate.  Because microrafts are approximately 11 times 
smaller than the wells, they can be positioned at various locations at the bottom of 
the well.  Therefore, to realize the potential for the microraft array technology and 
increase throughput for high-content screening, we focused on centering the small 
microrafts within the microtiter wells to facilitate automated imaging.  To do this we 
developed a special magnet array plate which functions as a centering device to fully 
exploit the advantages of using microraft arrays for screens. 
4.2 Materials and Methods 
4.2.1 Design and Analysis 
3D modeling and detailed drawings of the magnet array plate were created 
using SolidWorks 2012 (Dassault Systemes).  Finite element analysis was 
performed using COMSOL Multiphysics Version 4.3 (COMSOL Inc.).  Model I was 
created axial symmetrically, while Models II & III were created three dimensionally.  
In all cases the magnets were modeled with a relative permeability of neodymium of 
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1.05 and a remanent flux density of 1.48T which is characteristic of a 52 MGOe 
neodymium magnet.  A “physics controlled” extra fine mesh was use in all models. 
4.2.2 Magnet Array Plate Materials 
The magnet array plate was fabricated from LEXAN polycarbonate.  384 
magnets (Model D14-N52, K&J Magnetics, Inc.) were used for the plate. The 
magnets were cylindrical in shape with a diameter of ~1.6 mm and a length of 6.35 
mm.  These magnets are made of grade N52 NdFeB with a NiCuNi plating and a 
maximum field strength of 1.48 T. 
4.2.3 Magnet Array Plate Fabrication 
The magnet array plate was fabricated via a CNC milling process.  Holes 
were drilled at max tolerance.  Following the machining process, the magnets were 
inserted by hand and/or glued with cyanoacrylate when a snug fit was not available. 
4.2.4 Microraft Array Fabrication 
Microraft arrays were fabricated according to previously published methods10; 
11.  Briefly, soft lithography was used to make the poly(dimethylsiloxane) (PDMS) 
template containing an array of microwells (each well has width x length x height = 
500 µm x 500 µm x 200 µm, array size = 25.4 mm x 25.4 mm).  The PDMS template 
was then dip coated with a 20% polystyrene solution in gamma-butyrolactone (GBL) 
containing 4% iron oxide particles.  The arrays are then placed in a convection oven 
at 95C for 16 hours to evaporate GBL to create the microrafts. The array was glued 
to a polystyrene cassette to facilitate handling, and then surface treated with air 
plasma Harrick Plasma) for 2 min. 
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4.2.5 Microraft Transport 
For this study microrafts were ejected from the array and individually 
transported to microtiter plates in ~5 µl volumes using a single channel pipette with a 
large orifice tip (Fisher Scientific; 02-707-134).  Microtiter plates used for this study 
were 384-well Small Volume, LoBase, Polystyrene, µClear, black, tissue culture 
treated, sterile plates (Greiner BioOne; 788092) 
Centering Performance Assessment 
Centering performance was evaluated based on the percent centering and centering 
efficiency as follows (see Fig. 4): 
% 𝐶𝑒𝑛𝑡𝑒𝑟𝑖𝑛𝑔 =
(𝐿 − 𝑑)
𝐿
∗ 100 
Where: 
L = The distance from the center of the well to the center of the 
microraft when it is located flat on the bottom and against the 
edge of the well. (0.643 mm for Greiner BioOne 788092) 
d = The distance from the center of the well to the center of the 
microraft at the position where it rests in the well. 
 
𝐶𝑒𝑛𝑡𝑒𝑟𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
# 𝑊𝑒𝑙𝑙𝑠 ≥  75% 𝐶𝑛𝑡.  
𝑇𝑜𝑡𝑎𝑙 # 𝐶𝑒𝑛𝑡𝑒𝑟𝑒𝑑 𝑊𝑒𝑙𝑙𝑠
 
Please note that in calculating centering efficiency, the value of % centered 
was taken relative to 75% as this value of centering represents that a sufficient 
portion of the centered microraft is within the field of view for automated imaging. 
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4.2.6 Cell Culture 
All animal procedures were carried out in accordance with the University of 
North Carolina at Chapel Hill Institutional Animal Care and Use Committee (IACUC).  
Dissociated hippocampal cultures were prepared at embryonic day 18 from Sprague 
Dawley rat embryos as previously described14 with some modifications.  Briefly, 
hippocampal tissue was dissected in dissociation media (DM) containing 82mM 
Na2SO4, 30mM K2SO4, 5.8mM MgCl2, 0.25mM CaCl2, 1mM HEPES, 20mM 
Glucose and 0.001% Phenol red.  Equal volumes of TrypLE Express (Invitrogen) 
and DM were added to the tissue and incubated at 37°C for 8 min.  Tissue was then 
rinsed and gently triturated in Neurobasal media (NBM, Invitrogen) supplemented 
with 1x B27 (Invitrogen), 1x Antibiotic-antimycotic (Invitrogen), 1x Glutamax 
(Invitrogen).  Dissociated cells were then centrifuged (67xg) for 7 minutes at 4°C, 
and resuspended (12x106 neurons/mL) in NBM.  Prior to cell dissociation, microraft 
arrays were coated with poly-D-lysine (80 µg/mL; high molecular weight – 500-550 
kDa) at 37˚C overnight and then rinsed three times with PBS.  Neurons were then 
plated on the poly-D-lysine-coated raft arrays (1 million neurons/array). Rafts were 
released the following day and maintained in NBM until 8 DIV. We released and 
transferred the microrafts after 1 DIV because at this stage their processes are not 
long enough to extend over the PDMS borders between the microrafts while they are 
still embedded in the array.  Waiting longer to release and transfer microrafts may 
cause injury to the neurons through shearing of processes that have grown over the 
borders. 
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4.2.7 Fluorescent dye labeling 
The cell viability assay was performed as described previously9.  Briefly, cells 
were grown for 8 DIV and then stained with a solution containing Sytox Green 
Nucleic Acid Stain (1:1000; Life Technologies, Inc.) and NucBlue Live Cell Stain 
Ready Probes/ Hoechst33342 (2 drops/mL; Life Technologies, Inc.) for 5 minutes at 
room temperature to label dead/dying cell nuclei and all cell nuclei respectively.  
Following staining, the cells were rinsed three times for two minutes each with PBS 
and then fixed for 30 minutes with 4% formaldehyde.  After fixation, cells were rinsed 
three times for two minutes each with PBS and finally placed in 0.1% NaN3 before 
imaging. 
4.2.8 Imaging and Image Processing 
Imaging was performed on an Andor XDi imaging system featuring a 
Yokogawa spinning disk confocal unit and an Olympus IX81-ZDC2 inverted 
microscope with a motorized stage by Ludl as described previously 15.  The speed of 
image acquisition of this spinning disk confocal imaging system is comparable to 
high content imagers (e.g., the BD Pathway) with a scan speed of 36 sec per well for 
2-channel fluorescence. 
Montages (2 x 2) were taken of each microraft with a 20X objective and 
stacks ranging from 10 – 20 slices each spaced 0.85 µm (z-distance) apart.  Dead 
cells stained by Sytox were captured using 488 nm laser excitation and a 525-30nm 
single band fluorescence filter (Semrock Brightline), while the cell nuclei 
representing all cells were captured using 405 nm laser excitation and a 447-60nm 
single band fluorescence filter (Semrock Brightline).  After acquisition, all images 
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were analyzed with ImageJ as described previously 9. Briefly, images were imported 
using the Bio-formats plugin, slices were summed using maximum intensity 
projection, and then converted to 8-bit. The projected images were thresholded and 
the number of stained nuclei were counted within a 300 µm diameter region of 
interest in the center of the rafts using the ‘Analyze Particles’ command. 
4.2.9 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 software.  Mean 
percent centering, centering efficiency, and percent viability were plotted as mean ± 
SEM.  Statistical significance was tested with a nonparametric Mann-Whitney test.  
Statistical significance with p-values < 0.01 are indicated with asterisks.  Correlation 
values for the magnetic field analysis were calculated using Microscoft Excel’s 
correlation function which is based on the sample Pearson correlation coefficient. 
4.3 Results  
4.3.1 Design and Fabrication of Magnet Array Plate 
The goal was to design a magnet array plate that would center microrafts 
within each well of a standard 384-well microtiter plate and be compatible with high-
throughput fluid handling systems. The design of the magnet array plate began with 
the ANSI/SLAS 2004 micro-titer plate standard footprint, which has been adopted by 
all major manufacturers and defines the outside footprint and corner radius of all 
micro-titer plates regardless of their well density.  Using this standard and typical 
well-to-well spacing found in 384-well microtiter plates, the geometry of the magnet 
array plate was designed in plan (Figure 4.1C). 
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In this design the magnets were positioned at the centers of each well with a 
center–to-center distance of 4.5 mm.  Port holes located on the bottom of the plate, 
centered under each magnet, allow the insertion and ejection of the magnets at-will 
(Figure 4.1D). The outer rim of the plate is approximately 5 mm thick and serves to 
frame and secure the microtiter plate it supports. 
The plate was designed to adapt with commonly used high-throughput fluid 
handling machines (e.g., Tecan or Hamilton) (Figure 4.1D).  To magnetically secure 
the microrafts during automated fluid handling operations, we designed the magnet 
array plate to fit within fluid handling plate brackets designed for ANSI/SLAS 2004 
microtiter plate footprints.  The tops of the magnets were positioned flush with the 
top of the inside plate face and 2 mm above the channel.  This design feature was 
intended to adhere to the design of low base microtiter plates such that the magnets 
are flush against the bottoms of these plate types.  Low base plates are most 
commonly used in automated imaging as they facilitate the imaging of all wells 
including those located on edges, and the flushness of the mangnets is important for 
maximum attraction and centering of the microrafts to the bottom of the microtiter 
wells.The final design was machine milled from LEXAN polycarbonate, and features 
384 neodymium magnets (Figure 4.1E and F). 
4.3.2 Magnetic Field Analysis 
Finite element modeling and analysis was performed to assess the nature of 
the magnetic field of the cylinder magnets relative to microrafts at various positions 
within the microtiter wells (Figure 4.2A).  We modeled commercially available 
magnets and analyzed 1.5 mm diameter (smallest practical size for fabrication) and 
108 
 
1.6 mm diameter magnets which are both similar in diameter to wells of a low-base 
384-well plate. Results using the 1.5 mm diameter (results not shown) and 1.6 mm 
diameter cylinder magnets clearly showed that the magnetic field in the axial 
direction peaked at the center of the magnet (Figure 4.2B) while the field in the 
radial direction peaked at the edge of the magnet (Figure 4.2C).  Furthermore, both 
magnetic fields followed a non-linear decay the further away from the surface of the 
magnet (Figure 4.2D).  Since the magnetic field in the radial direction peaks at the 
edge of the magnet it is more beneficial to use a magnet with a similar diameter to 
the bottom of the well thus allowing the magnetic field in axial direction which peaks 
at the center to dominate and better serve to center the microrafts.  The 1.6 mm 
diameter magnet is nearly coincident with the area of the bottom of the well, so this 
magnet was selected and used in the remainder of the study. 
We next analyzed whether field interference existed between adjacent 
magnets.  We created a model with two magnets spaced exactly at the center-to-
center distance of adjacent wells.  When analyzing the magnetic field in both the 
axial and radial directions (Figure 4.2E and F), we found a strong correlation (radial 
correlation = 0.986, axial correlation = 0.994) for both directions between the field of 
multiple magnets and that of a single magnet.  Since the fields for multiple magnets 
were so similar to that of a single magnet we were able to conclude that there is no 
interference between adjacent magnets in our designed magnet array plate. 
4.3.3 Magnetic Force Analysis 
With the proper size of the magnet determined and the nature of the 
interaction between adjacent magnets understood, we next sought to determine the 
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force experienced by the microrafts at various locations within the microwells.  It was 
important for us to understand the general trends of these forces in terms of how the 
forces on the microrafts relate to each other as their position changes both axially 
and radially within the well, but also how those forces relate to the force required to 
move the raft from a stationary positon on the well bottom which was calculated 
kinematically.  Forces were analyzed at center, quarter, and edge positions and 
heights ranging from 0 – 600 µm above the bottom of the micro titer plate to evaluate 
the influence of different locations where the rafts would be positioned following 
transfer (Figure 4.3A).  In the radial direction (Figure 4.3B) all locations were 
significantly less than the forces experienced in the axial direction, however these 
forces were still greater than the calculated 4.54 x 10 -8 N force required to move a 
stationary microraft on the bottom of the microwell.  The forces in the axial direction 
were clearly dominant over those in the transversal direction, due in large part to the 
size of the magnet relative to the microwell as previously discovered.  More 
significant however was that for similar lateral positions (i.e. center, quarter, and 
edge locations), the forces were approximately the same (Figure 4.3C).  This 
implies that microrafts falling along the side of the wall would still be centered. 
4.3.4 Centering Performance Evaluation 
After performing finite element analysis supporting the proper design of the 
magnet array plate, we next wanted to experimentally test the performance of our 
prototype.  Our goal was to first test the effectiveness of centering using the magnet 
array plate compared to the use of a conventional flat magnet. We wanted to 
determine whether having the magnet array plate in place during loading or after 
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loading would yield equivalent centering efficiencies. The metrics used in these tests 
include percent centering and centering efficiency which are formulated in the 
Methods section (Figure 4.4A and B).  Percent centering measures the amount the 
microraft is centered, with the center of the microtiter plate well coincident with the 
center of the microraft equal to 100% and the center of the microraft with one edge 
abutted against the edge of the well equal to 0%.  This metric is calculated as the 
fraction of the distance from the center of the microtiter plate well to the center of the 
microraft divided by the distance from the center of the microtiter plate well to the 
center of the microraft when its edge is abutted against the edge of the well.  To 
calculate the centering efficiency, we counted the number of times percent centering 
was greater than or equal to 75% and divided that by the total number of wells 
where rafts were not flipped on edge. 
In our first test, the microtiter plate was positioned on top of the magnet array 
plate during loading of the microrafts (Test 1), and individual microrafts were 
transferred to the wells using a pipette as described in Methods.  The centering 
performance of the magnet array plate was compared to a flat magnet plate which 
contains a single flat plate magnet with an area similar to that of the microtiter plate, 
and a control sample which used no magnets.  The magnet array plate showed a 
mean percent centering of 88.16% compared to 7.8% for the flat magnet plate and 
35.85% for the control (Figure 4.4C and D).  For the centering efficiency, the 
magnet array plate performed at 100% versus 4.35% for the flat magnet plate and 
17.86% for the control (Figure 4.4E), demonstrating that whenever the magnet array 
plate is in use, it centers the microrafts to 75% or better. This is excluding the 
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number of times the microrafts flipped on edge.  For the magnet array plate this 
happened 10% of the time while the flat magnet plate was 20% and the control was 
3% (Figure 4.4F).  When the microrafts land on their edge it renders that well 
useless in a high content screen because the cells cannot be imaged, therefore it is 
critical to know the frequency in which this happens.  We believe however that the 
times in which microrafts flipped on their edge can be attributed to a small amount of 
magnets that were placed in the reverse direction while manually inserted during the 
fabrication process.  Furthermore we believe that this statistic can easily be 
decreased by correcting this problem and increasing our sample size. 
Although it did not occur in this study, in rare instances microrafts may land 
cell side down.  However, in these instances neither screening nor imaging is 
affected because the microrafts are slightly concave on their top surface which 
prevents the adhered cells from coming in contact with the bottom of the well when it 
lands cell side down.  This concavity also conveniently allows for similar objective 
distances whether or not the microraft is cell side up or cell side down11.  We found 
that the microrafts land cell side up the majority of the time and we believe this may 
be attributed to the drag created from the slight concavity on the top surface of the 
microrafts. 
To observe whether the magnet array plate was able to center microrafts after 
microraft loading, we loaded microrafts into the micro-titer plate, let them settle, and 
then placed the microtiter plate on top of the magnet array plate (Test 2).  Images 
show that the microrafts were initially scattered within the wells, but after placing the 
micro-titer plate on the magnet array plate, centering was achieved (Figure 4.4G).  
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When quantified, the mean centering was 10.8% before placement versus 78.1% 
after placement (Figure 4.4H).  Finally, comparing the technique used in Test 1 
versus Test 2, the centering efficiency was 100% versus 66.7% respectively (Figure 
4.4I).  This result shows that to best achieve centering, it is better to first place the 
microtiter plate on top of the magnet array plate before loading the microrafts.  
However should the microrafts become decentered as the result of the movement or 
the plate being hit, centering can still be achieved by placing the loaded microtiter 
plate back on the magnet array plate.  We’ve determined however that dislodging of 
the microrafts is unlikely as it would require moving the plate at a speed of 5.66 ft/s 
(calculation not shown) and stopping abruptly in order to create enough inertial force 
to overcome the frictional forces holding the raft in place. 
4.3.5 Cell Viability Evaluation 
We successfully demonstrated the ability of the magnet array plate to center 
microrafts. As a final measure of performance, we tested whether centering the 
microrafts affected cell viability.  With the added acceleration of the microrafts, 
beyond that of gravity, due to the attractive force of the magnet, there was some 
concern that increased fluid shear forces may endanger the neurons attached to the 
microrafts.  To determine if this was a threat, a cell viability assay was performed to 
determine the differences in viability between unreleased microrafts, microrafts 
which have been released and transferred, and microrafts which have been 
released, transferred, and centered. 
Primary hippocampal neurons were plated on a microraft array at a density of 
1 million cells.  After 1 DIV the microrafts were released from the array and 
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transferred to a 384-well micro titer plate.  At 8 DIV cell viability was quantified using 
a live/dead assay and immunostaining for MAP2 was used as a neuronal marker to 
characterize neuronal morphology (Figure 4.5A, B).  After imaging and 
quantification, the results showed that centering the cells had no significant effect on 
cell viability compared to unreleased or released and transferred microrafts (Figure 
4.5C). 
4.4 Conclusions 
Although other magnetic plates exist commercially, mostly used for PCR 
assays, these plates are usually designed for 96-well microtiter plates, and operate 
by pulling magnetic beads to the side of the wells.  To the authors’ knowledge, the 
magnet array plate described herein is the only one designed for high throughput 
screening in 384-well microtiter plates and is unique in that it centers microraft 
culture platforms which offer the opportunity to scale-up screening for neurological 
diseases. 
With a well-to-well spacing half that of 96-well microtiter plates, fabricating a 
384 magnet array plate can be difficult because of the risk of thermally induced 
cracking when drilling the magnet holes.  For this reason we wanted to use a hard 
plastic with a low glass transition temperature to comply with the heat produced 
during machining.  LEXAN is form of polycarbonate which has a relatively low glass 
transition temperature and an extremely low thermal expansion coefficient, which 
allows it to be machined relatively easily without cracking. 
Another factor in the fabrication of the plate was imaging.  Importantly, we 
found that after the magnet array plate centers the microrafts, they remain in place 
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after removing the magnet array plate and also while subjected to mild perturbations.  
Thus it is unnecessary for the magnet array plate to be in place during imaging.  
However, an additional reason why LEXAN was chosen was its semi-translucency.  
This characteristic is beneficial for situations in which microrafts must be centered 
and secured while simultaneously performing tasks and imaging stereoscopically. 
In creating the magnet array plate, one of the unique design features is its 
ability to fit within commercial fluid handling machines which allows it to secure the 
microrafts during fluid processes while preserving their centered position for 
imaging.  In honing this design we conducted a thorough analysis and concluded 
that it was better to use magnets similar in diameter to the microtiter well in order to 
achieve the best centering results.  Smaller magnets would trap the microrafts at the 
magnet edge where the field in the radial direction peaks, and prevent centering.  
Our design decision was confirmed by our empirical results which not only showed a 
centering efficiency far beyond that of a flat magnet plate, but also proved that it is 
preferable to have the magnet array plate positioned under the microtiter plate prior 
to loading the microrafts.  This conclusion concurred with our analysis that microrafts 
loaded with a magnetic field already in place aligned themselves with the axial field 
and they were drawn towards the center where this field peaks.  However when 
loaded prior to placement of the magnetic field, the settled microraft at the bottom of 
the well must rely on a weak radial field to be centered.  Although this radial field is 
weaker, we found that centering occurred after microrafts randomly settled within the 
microtiter plate well as shown in Test 2.  This result is important in the event that 
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microrafts become dislodged from their centered position, although our calculations 
show it would take a significant amount of acceleration for dislodging to occur. 
Finally, viability experiments further validated the effectiveness of the magnet 
array plate proving that neither transporting, nor transporting and centering create 
adverse effects on cell viability.  These experiments concluded the overall success 
of this tool as a device to center paramagnetic microraft culture platforms for 
automated imaging, opening the opportunity for these microrafts to reduce costs, 
preserve animal life, increase throughput, and make cell-based screens of 
neurological disorders more accessible. 
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4.5 Tables & Figures 
 
Figure 4.1.  Microraft arrays and three dimensional modeling and drawings of 
the magnet array plate. (A) Photograph of microraft array with schematic 
drawing showing dimensions. (B) MAP2 immuno stained neurons cultured on 
a single microraft. (C-D) Computer-aided design (CAD) drawings of magnet 
array plate, plan and section views. (E) Photograph of magnet array plate. (F) 
CAD renderings of the magnet array plate in isometric view.  
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Figure 4.2.  Results of the magnetic field analysis of a microraft at various 
heights within a microtiter plate well.  The magnetic field peaks in the center 
and edge in the axial and radial directions of the microwell, respectively.  
Adjacent magnetic fields do not interfere.  (A) Analysis positions of microrafts 
(in µm) in the axial (Z) direction.  Red rectangles represent microrafts.  (B) 
Magnetic field in the axial direction.  (C) Magnetic field in the radial direction.  
(D) Magnetic field decay curves.  (E) Dual magnet field in the axial direction.  
(F) Dual magnet field in the radial direction.  For B and C, the red dashed line 
represents the outside edge of the cylinder magnet.  For E and F, the red 
dashed line represents the center axis of the cylinder magnet.  
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Figure 4.3.  Magnetic force analysis of microrafts at different axial (Z) and 
radial positions.  (A) Analysis positions of microrafts (in µm) in the axial 
direction in the center, quarter, and edge of the well, respectively.  Rectangles 
represent microrafts.  (B) Magnetic force on microraft in the radial direction.  
(C) Magnetic force on microraft in the axial (Z) direction.  
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Figure 4.4.  The magnet array plate effectively centers the microrafts.  (A) 
Percent centering metric in which 100% represents the center of the microwell 
and 0% represents the microrafts abutted against the microwell.  d represents 
the distance of the microraft from the center of the microwell, and L is the 
distance between 0% and 100% centering. (B) Centering efficiency in which 
the red dashed line represents a ≥75% centered value.  (C) Representative 
images of Test I centering. (D) Test I mean percent centering. (E) Test I 
centering efficiency. (F) Percentage of microrafts flipped on edge. (G) 
Representative images of Test 2 centering. (H) Test 2 mean percent centering. 
(I) Overall technique efficiency.  For all n=30.  ****=p<0.0001; scale bar = 500 
µm.  
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Figure 4.5.  Cell viability was not affected by the transfer and centering 
process.  (A) neurons cultured for 8 days on released and transferred 
microrafts are immunolabeled for MAP2 (red), a neuron specific marker; scale 
bar = 250 µm. (B) Merged image of MAP2 (C) Percent viability results (n=12 
wells). Stain located off of microraft is dead cell debris.  
121 
 
4.6 BIBLIOGRAPHY 
1. Gordon KR, Wang YL, Allbritton NL, Taylor AM. 2015. Magnetic alignment of 
microelements containing cultured neuronal networks for high-throughput 
screening. Journal of Biomolecular Screening. 20(9):1091-1100. 
2. Zhang MH, Luo GR, Zhou YJ, Wang SH, Zhong Z. 2014. Phenotypic screens 
targeting neurodegenerative diseases. Journal of Biomolecular Screening. 
19(1):1-16. 
3. An WF, Tolliday NJ. 2009. Introduction: Cell-based assays for high-throughput 
screening. In: Clemons PA, Tolliday NJ, Wagner BK, editors. Cell-based 
assays for high throughput screening: Methods and protocols. New York, NY: 
Human Press. p. 218. 
4. Al-Ali H, Schuerer SC, Lemmon VP, Bixby JL. 2013. Chemical interrogation of the 
neuronal kinome using a primary cell-based screening assay. Acs Chemical 
Biology. 8(5):1027-1036. 
5. Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, 
Dutton JW, Lee HM, Chen X et al. 2012. Topoisomerase inhibitors unsilence 
the dormant allele of ube3a in neurons. Nature. 481(7380):185-+. 
6. Götte M, Hofmann G, Michou-Gallani A-I, Glickman JF, Wishart W, Gabriel D. 
2010. An imaging assay to analyze primary neurons for cellular neurotoxicity. 
Journal of Neuroscience Methods. 192(1):7-16. 
7. Biffi E, Regalia G, Menegon A, Ferrigno G, Pedrocchi A. 2013. The influence of 
neuronal density and maturation on network activity of hippocampal cell 
cultures: A methodological study. PLoS One. 8(12):e83899. 
8. Moraes C. 2015. The discovery channel: Microfluidics and microengineered 
systems in drug screening. Integrative Biology. 
9. Niedringhaus M, Dumitru R, Mabb AM, Wang Y, Philpot BD, Allbritton NL, Taylor 
AM. 2015. Transferable neuronal mini-cultures to accelerate screening in 
primary and induced pluripotent stem cell-derived neurons. Sci Rep. 5:8353. 
10. Gach PC, Wang Y, Phillips C, Sims CE, Allbritton NL. 2011. Isolation and 
manipulation of living adherent cells by micromolded magnetic rafts. 
Biomicrofluidics. 5(3):32002-3200212. 
11. Wang YL, Phillips C, Xu W, Pai JH, Dhopeshwarkar R, Sims CE, Allbritton N. 
2010. Micromolded arrays for separation of adherent cells. Lab on a Chip. 
10(21):2917-2924. 
12. Al-Ali H, Blackmore M, Bixby JL, Lemmon VP. 2013. High content screening with 
primary neurons. In: Sittampalam G, Coussens N, Nelson H, editors. Assay 
122 
 
Guidance Manual [Internet]. Bethesda, MD: Eli Lilly & Company and the 
National Center for Advancing Translational Sciences. 
13. Jones E, Michael S, Sittampalam GS. 2012. Basics of assay equipment and 
instrumentation for high throughput screening. In: Sittampalam G, Coussens 
N, Nelson H, editors. Assay Guidance Manual [Internet]. Eli Lilly & Company 
and the National Center for Advancing Translational Sciences. 
14. Taylor AM, Wu J, Tai HC, Schuman EM. 2013. Axonal translation of beta-catenin 
regulates synaptic vesicle dynamics. J Neurosci. 33(13):5584-5589. 
15. Hallfors N, Khan A, Dickey MD, Taylor AM. 2013. Integration of pre-aligned liquid 
metal electrodes for neural stimulation within a user-friendly microfluidic 
platform. Lab on a Chip. 13(4):522-526. 
123 
 
 
Chapter 5: Protein Measurement Assay using Microrafts 
5.1 Introduction 
One of the most direct approaches for discovering new treatments for fragile x 
syndrome is to identify compounds that unsilenced the fmr1 gene and produce 
FMRP.  In recent years assays have been developed to detect and measure FMRP 
in a number of ways. 
In 2009 Iwahashi developed a quantitative enzyme-linked immunosorbent 
assay (ELISA) to detect FMRP in peripheral blood lymphocytes.  Using 96-well 
plates and luminescence as a readout, this assay proved to be accurate and reliable 
in detecting FMRP throughout the biologically relevant range of protein 
concentrations.1 
In a similar yet less complex approach, Schutzius developed a time-resolved 
Forster’s resonance energy transfer (TR-FRET) assay for measuring FRMP using 
maltose binding protein (MBP)-FMRP and patient peripheral blood mononuclear 
cells.  This assay was performed in 384-well format with 5 µL of sample lysate per 
well.2  Following this development, in 2015 Kumari, also using a TR-FRET assay 
performed a screen of 5,000 compounds to identify candidates which increase 
FMRP expression in patient iPSC-derived neural stem cells.  Using a standard plate 
reader for detection, cells were screened in a 1,536-well format with 2,500 cells per 
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well.  Unfortunately, this screen produced six hits which only produced small 
increases in FMRP expression.3 
Finally, in another approach, Kaufmann et al. in 2015 used a high-content 
imaging assay to screen 50,000 compounds to identify potential candidates which 
upregulate production of FMRP in patient iPSC-derived neural progenitor cells.  In 
this process, cells were fixed and stained with an anti-FMRP antibody in a 384-well 
format with 20,000 cells per well.  The screen identified only a small subset of 
compounds that produced a weak but noticeable expression of FMRP.4 
In this chapter an assay is developed to measure FMRP from recombinant 
sources as well as cell lysate in an effort to demonstrate the use of microrafts in a 
scalable high-throughput screening assay.  This assay is composed of a two stage 
process in which the microrafts in each well are first quantified in a high-throughput 
manner to normalize the resulting data, and then FMRP is measured.  Two 
approaches were explored for the FMRP detection including a bead-based ELISA 
using flow cytometric for data acquisition and an immunofluorescence assay. 
5.2 Methods 
5.2.1 Rhodamine B Microraft Fabrication 
Microrafts were infused with Rhodamine B (Sigma R6626) fluorescent dye by 
adding it to the magnetic polystyrene solution at 0.01 wt%.  The solution was then 
mixed for >1 hr on a standard bottle roller for even distribution.  The microrafts were 
then created through the dip-coating process as previously described. 
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5.2.2 Quantification of Microrafts 
Microrafts were quantified via fluorescence using a Perkin Elmer Envision 
2103 multilabel plate reader.  Fluorescence detection was set to the emission 
spectra wavelength of Rhodamine B and measurements were conduction in a well-
to-well sequential order with 25 (5 x 5) detections per well.  The protocol was 
optimized for Greiner Small Volume, Lo Base, 384-well microtiter plate (788096). 
5.2.3 Cell Culture 
All animal procedures were carried out in accordance with the University of 
North Carolina at Chapel Hill Institutional Animal Care and Use Committee (IACUC).  
Dissociated hippocampal cultures were prepared at embryonic day 18 from Sprague 
Dawley rat embryos as previously described5 with some modifications.  Briefly, 
hippocampal tissue was dissected in dissociation media (DM) containing 82mM 
Na2SO4, 30mM K2SO4, 5.8mM MgCl2, 0.25mM CaCl2, 1mM HEPES, 20mM 
Glucose and 0.001% Phenol red.  Equal volumes of TrypLE Express (Invitrogen) 
and DM were added to the tissue and incubated at 37°C for 8 min.  Tissue was then 
rinsed and gently triturated in Neurobasal media (NBM, Invitrogen) supplemented 
with 1x B27 (Invitrogen), 1x Antibiotic-antimycotic (Invitrogen), 1x Glutamax 
(Invitrogen).  Dissociated cells were then centrifuged (67xg) for 7 minutes at 4°C, 
and resuspended (12x106 neurons/mL) in NBM. 
5.2.4 Cell Lysis and Recombinant FMRP 
Cells were lysed using RIPA buffer (Sigma R0278) according to the 
manufacturer’s procedure.  Briefly, growth media was first aspirated from the cells.  
Then cells were gently washed twice with DPBS.  Ice cold RIPA buffer was then 
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added to each well and incubated on at 4°C for five minutes.  The cellular material 
was then scraped from the coverslips and aspirated up and down vigorously 3-4 
times.  On the last aspiration, the cell lysate is removed and placed in a chilled tube 
and centrifuged at at 8,000 g for 10 minutes at 4°C to clarify.  Finally, the lysate was 
stored at -80°C for later use. 
 For experiments using recombinant protein, FMRP overexpression lysate 
(native) (Novus Biologicals NBP2-08154) was used.  This protein was created from 
plasmid transfected HEK293T cells based on NP_002015. 
5.2.5 ELISA Assay 
 DevScreen Streptavidin QBeads (Intellicyt Inc.) were briefly centrifuged.  The 
bead vial was then Vortexed for ~30 seconds to thoroughly mix the beads.  The 
appropriate volume of bead solution was then tranfered to a 1.5 mL microcentrifuge 
tube.  The sample was then centrifuged at 8,000 g for 5 minutes followed by removal 
of the supernatant and resuspension in the appropriate volume of PBS-1%BSA.  
Capture antibody (US Biological, F6072-10G-Biot) was then added to the bead 
solution at the necessary concentration and the combined solution was vortexed to 
evenly mix.  The bead-capture antibody solution was then incubated at room 
temperature for 2 hrs. 
 Following incubation, the bead-capture antibody solution was washed twice 
by centrifuging at 8,000 g for 5 minutes, removing the supernatant, adding PBS-
1%BSA and repeating.  Ten microliters of this solution were then added to each well 
of a 384-well plate.  Ten microliters of sample (lysate, recombinant FMRP) were 
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then added to the solution in each well and this combination was incubated 
overnight at room temperature on an orbital shaker. 
 Following overnight incubation, 10 µL of detection antibody (Developmental 
Studies Hybridoma Bank, University of Iowa, 2F5-1-s) solution at the appropriate 
concentration was added to this rest of the mixture.  The combined solution was 
then incubated for 1 hour at room temperature.  Lastly, the secondary conjugated 
antibody was added and incubated room temperature for 1 hour. 
5.2.6 Flow Cytometry 
FMRP was measured on an iQue Screener Plus (Intellicyt Inc.).  The settings 
were used in data acquisition: 
Laser acquisition: blue 
Pre-plate shake: 180 secs at 1800 rpm 
Sip time: 30 sec 
Pump speed: 19 rpm 
 
5.2.7 Immunofluorescence 
For the final immunofluorescence assay, media was first removed from the 
384-well plate and replaced with the same volume of Neurobasal media containing 
DRAQ5 nuclear dye (1:500; Thermo Scientific).  After incubating for five minutes at 
37°C, the dye solution was aspirated and cells were fixed for 30 minutes with 4% 
formaldehyde in PBS containing 40 mg/ml sucrose 1 µm MgCl2, and 0.1 µm CaCl2.  
After fixation, cells were rinsed three times for two minutes each with PBS.  Neurons 
were permeabilized in 0.25% Triton X-100 for 15 min and then blocked in PBS 
containing 10% goat serum for 15 min.  Primary antibodies to FMRP (1:10; mouse ; 
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2F5-1 [developed by Tartakoff, A.M./Fallon, J.R. and obtained from the 
Developmental Studies Hybridoma Bank developed under the auspices of the 
NICHD and maintained by the University of Iowa, Department of Biology, Iowa City, 
IA 52242]) was diluted in PBS with 1% goat serum and incubated overnight at 4°C.  
AlexaFluora goat anti-mouse conjugated to a 488 nm fluorophore (1:1000; 
Invitrogen) was diluted in PBS and incubated for 1 h at room temperature. 
5.2.8 Image Acquisition 
 Imaging was performed on an Olympus FV1000 inverted confocal microscope 
with motorized stage.  Images were capture with a 20X LUCPLFLN objective and a 
488 nm multiline Argon laser and 633 nm Helium-Neon laser for FMRP and DRAQ5 
excitation respectively. 
5.2.9 Image Analysis 
After acquisition, all images were analyzed with ImageJ. Images were 
imported using the Bio-formats plugin, slices were summed using maximum intensity 
projection, and then converted to 8-bit. The 488 nm and 633 nm channels were split, 
and the projected images were thresholded.  The area of FMRP was quantified 
within a 300 µm diameter circular region of interest in the center of the microrafts 
using the ‘Analyze Particles’ command. 
5.2.10 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 software.  FMRP 
area was plotted as mean ± SEM.  Statistical significance was tested using one-way 
ANOVA with p-values < 0.001 are indicated with asterisks. 
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5.3 Results 
 5.3.1 Quantification of Microrafts 
 Measuring cellular FMRP using microrafts where more than one raft is in 
each well requires normalization of the data, so each well can be properly compared 
to each other.  Therefore, in order to count the number of microrafts per well in a 
high-throughput fashion, a method was conceived were the microrafts were infused 
with fluorescent dye, and then the fluorescence would be detected using a plate 
reader.  Thus, the number of rafts would be proportional to the fluorescence intensity 
of the well. 
 To test this concept, an initial experiment was designed and performed 
(results not shown) to insure that Rhodamine B could be detected in small volumes.  
For this experiment, Rhodamine at 0.01 wt% (the same concentration used for the 
microrafts) was aliquoted at 10 µL per well, and controls of Celltiter Glo, and blank 
wells were used to assess the difference in fluorescence.  With wells containing 
Rhodamine, Celltiter Glo, Rhodamine plus Celltiter Glo, and blank wells, it was 
observed that the Rhodamine was easily detected above the Celltiter Glo which is 
normally detected through luminescence, not fluorescence.  Furthermore, at 50 µL, 
the Rhodamine showed at higher fluorescence demonstrating a certain scaling effect 
of the signal. 
 With this information, the microrafts were fabricated with the Rhodamine B as 
described in the Methods section.  Arranged in populations of 0, 1, 2, 3, 4, and 5 
microrafts as well as a random population (Figure 5.1), the plate was scanned using 
a Perkin Elmer plate reader.  This scan produces a heat map of each well and the 
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sums the total fluorescence for that well (Figure 5.2 and Figure 5.3A).  This 
process was greatly aided by the magnet array plate in centering the microrafts as it 
helped focus the fluorescence signal to the center of the well.  Using the midpoints 
between the min and max fluorescence for each group (Figure 5.3B), an algorithm 
was created to estimate the number of microrafts per well.  Testing this algorithm on 
the random population produced a 98% success rate at identifying the correct 
number of microrafts in those wells. 
 5.3.2 Development of Screening Assay 
 In order to demonstrate the high-throughput capability of the microrafts, a 
scalable screening assay needed to be developed to show that useful information 
related to a disease marker could be extracted in a cell-based screen.  In selecting 
the type of assay, it was critical to choose one with very high sensitivity because 
each microraft supports only a few hundred cells and thus produces a small amount 
of FMRP.  It was also important to choose an assay and platform that had high-
throughput capabilities.  For these reasons, a bead-based enzyme-linked 
immunosorbent assay (ELISA) was chosen using flow cytometry to interrogate each 
bead and measure any bound FMRP (Figure 5.4).  The iQue Screener Plus from 
Intellicyte Inc. was used for the flow cytometric analysis because it’s specifically 
designed for high-throughput applications, capable of working with 384- and 1536-
well plates. 
 5.3.2.1 Assay Proof of Principle 
 In the first experiment conducted, the previously described assay was tested 
with cell lysate from hippocampal rat neurons as a proof of principle.  The goal in this 
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case was to detect a signal produced from the capture of FMRP contained within the 
lysate compared to a set of controls.  After analyzing the results, it was observed 
that a significant signal was detected above the blank beads and the beads 
combined with capture antibody (Figure 5.5).  The sample signal was also higher 
than the last condition in which beads were combined with the capture antibody, 
detection antibody, and secondary antibody.  However, the difference between these 
signals was not statistically significant.  Furthermore, the result of such a high signal 
without the presence of lysate is a strong indication of non-specific binding of the 
detection and secondary antibodies. 
 5.3.2.2 Antibody Concentration Optimization 
 To determine the optimal capture and detection antibody concentration, 
various dilutions were tested including 1 100⁄ ,
1
250⁄ ,
1
500⁄ ,
1
1000⁄ ,
1
2000⁄  for the 
capture antibody combined with detection antibody in dilutions of 1 2⁄  ,
1
5⁄  ,
1
10⁄  .  
However, in analyzing the results (not shown), there was only minor differences in 
the fluorescence between these groups.  These unfortunate results were further 
evidence of non-specific binding. 
 In an effort to determine if the results of this experiment were affected by an 
environmental element, another experiment was conducted in which the capture 
antibody was diluted to 1 100⁄ ,
1
500⁄ ,
1
1000⁄  and the detection antibody was diluted 
to 1 2⁄  ,
1
5⁄  ,
1
10⁄  .  In both cases it was expected that signal would reduce 
according to reduction in the capture and detection antibody concentrations, but 
instead there was no clear trend.  As expected, the max and mean fluorescence for 
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these groups was above the negative control (beads + capture ab), however, 
compared to the other negative control (detection ab + secondary ab) they were 
almost equivalent.  It’s not exactly clear why the fluorescence levels for the second 
negative control were so high since there were no beads present, but it could 
possibly be due to aggregation of the antibody or somehow an errant bead or beads 
in the wells. 
 In addressing these errors another experiment was conducted in which the 
samples and controls were spread even further from each other on the plate in order 
to avoid errant beads that may have traversed into other wells during the shaking 
phases of the data acquisition protocol.  Additionally, the plate was washed before 
data acquisition to remove any loose antibody floating in the samples in an effort to 
reduce antibody aggregation.  Even with these measure however, there was still no 
clear trends among the dilutions and even some strange spikes in fluorescence 
representing inexplicable outliers.  Furthermore, controls without lysate but all the 
other components for the ELISA showed very high fluorescence indicating a high 
occurrence of non-specific binding of the antibodies. 
 In order to better assess the problem of non-specific binding and determine 
what the cause was, another experiment was devised eliminating the antibody 
dilution series and increasing the number of controls (Figure 5.6).  In addition, the 
recombinant FMRP was used at a low concentration (1/250) and a high 
concentration (1/50). 
 Upon removal of major outliers, it was clear from the analysis of this new data 
(Figure 5.7A and B) that the probable cause of the non-specific binding was due to 
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interaction between the bead and the secondary antibody or the capture antibody 
and the secondary antibody.  To investigate this hypothesis, another experiment was 
performed with very low and extreme dilutions of the secondary antibody with the 
logic that previous experiments had an excess amount (Figure 5.8).  Unfortunately 
even a vastly diluted secondary antibody only reduced, but did not eliminate the non-
specific binding problem (Figure 5.9).  And the presence of outliers only highlighted 
the inconsistencies between samples. 
 In a final effort to show that the same results arise when microrafts are used, 
primary hippocampal rat neurons were cultured on a microraft array.  After plating 
the neurons, the microrafts were released and transferred after 1 DIV and 
transferred to a 384-well plate for additional growth.  After 2 DIV the cells were 
lysed, and the lysate was used in the same bead-based ELISA as previously 
discussed.  Similar to the previous experiments however the samples did not create 
signals above that of the controls suggesting that the presence of the microrafts did 
not change the outcome in any way (Figure 5.10). 
 5.3.3 Immunofluorescence FMRP Measurement 
 Due to the surprising results of the bead-based ELISA, an 
immunofluorescence assay was performed to show that FMRP could be measured 
using the microrafts by other means.  Demonstrating FMRP immunofluorescence 
measurement is also important for its use in high-content screening. 
 For this experiment three microraft arrays were plated with densities of 1 MM, 
500 K, and 250 K respectively in order to show that different amounts of FMRP 
could be measured.  Blank microrafts were used as a control, and Draq 5 was used 
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as a co-localized stain of the nucleus.  Microrafts were released and transferred after 
1 DIV to a 384-well plate and then fixed and stained after 4 DIV. 
 Using confocal microscopy and FIJI image analysis, it was found that smaller 
cell densities produced significantly smaller amounts of FMRP (Figure 5.11).  
Furthermore, as previously reported, FMRP was localized around the cell nucleus as 
it serves as an mRNA shuttle protein (Figures 5.12 – 5.15). 
5.4 Conclusions 
 In using manual transfer methods such as the magnetic wand or pipette, it is 
important to have a high-throughput method for quantifying microrafts.  Regardless 
of the type of assay used, knowing the number of microrafts per well prior to data 
acquisition is important because this information allows you to accurately compare 
each well on a relative basis. 
 Fabricating the microrafts with Rhodamine B and scanning them with a 
standard plate reader produced very positive results, and it’s clear that this method 
represents a fast high-throughput solution for quantifying the microrafts.  Although 
there were some inconsistencies in fluorescence between plates, the main algorithm 
can be simply modified for each run sot maintain the high success rait in counting 
the microrafts. 
 It was unfortunate the quantification method could not be used for the bead-
based ELISA.  The bead-based ELISA, selected for its sensitivity, to measure FMRP 
overall failed to produce a signal significantly above the negative controls, and there 
were some inconsistencies between wells of the same sample groups.  Based on 
135 
 
analysis of the investigative experiments performed, it was clear that these results 
were caused by some sort of non-specific binding between the secondary antibody 
and the bead or capture antibody.  Unfortunately steps to ameliorate this such as 
dilution or plate washing did not have positive impacts on the outcome. 
 In theory, this bead-based ELISA should be effective in measuring small 
quantities of FMRP since each bead is individually interrogated in the flow 
cytometer.  Therefore, future efforts will require the testing of many types of beads, 
capture antibodies, as well as custom made detection antibodies preconjugated to 
fluorophores in order to eliminate the need for a secondary antibody.  Unfortunately 
the means for this type of campaign was not within the financial scope of this project. 
 As an alternative to the bead-based ELISA, immunofluorescence was used to 
measure FMRP, and this showed positive results.  FMRP could reliably be 
measured using image analysis, and was proportional to the cell density used.  Such 
results suggest that this approach could be used in a future high content screen.  
High content screening provides rich phenotypic information, but is also very costly 
and time consuming.  Such a endeavor requires optimization of cellular staining, 
image acquisition, and image analysis.  Future work along these lines would pair 
FMRP immunofluorescence with other morphologic and functional markers such as 
spine density and electrophysiology.  
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5.5 Tables & Figures 
 
 
Figure 5.1  384-well microplate experimental layout showing distribution of 
different numbers of microrafts per well. 
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Figure 5.2  Rhodamine B infused microrafts quantified using plate reader. (A) 
Plate reader heat-map showing variance in fluorescence relative to the number 
of microrafts per well. (B) 10X Images of microrafts in microwells from the 
“Random” group.  Scale bar in the image represents 250 µm (same for all 
images)  
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Figure 5.3.  Fluorescence signals for rhodamine B infused microrafts. (A) 
Mean fluorescence values for different size groups of microrafts per well. (B) 
Minimum and maximum fluorescence values for different size groups of 
microrafts per well.  
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Figure 5.4.  Bead based ELISA format (A) Streptavidin beads are centrifuged 
and washed. (B) Capture antibody is bound to streptavidin bead. (C) Cell 
lysate is incubated with bead-capture construct to bind FMRP. (D) Detection 
anti-FMRP and secondary conjugated antibodies are introduced in separate 
steps.  
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Figure 5.5.  FMRP detection using flow cytometer and a bead-based ELISA..  
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Figure 5.6.  384-well microplate experimental layout showing samples in red 
and yellow and controls in various colors.  
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Figure 5.7.  Flow cytometer fluorescence signals. (A) Mean fluorescence for 
high concentration and low concentration FMRP samples compared to 
controls. (B) Max fluorescence for high concentration and low concentration 
FMRP samples compared to controls.  
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Figure 5.8.  384-well microplate experimental layout showing samples in red 
and yellow and controls in various colors.  
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Figure 5.9.  Flow cytometer fluorescence signals. (A) Mean fluorescence signal 
of samples and controls at various secondary antibody dilutions. (B) Max 
fluorescence signal of samples and controls at various secondary antibody 
dilutions.  See Figure 5.8 for sample and control identifications.  
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Figure 5.10.  Flow cytometer fluorescence signals produced from the lysate of 
neurons grown on microrafts. (A) Mean fluorescence signal of samples and 
controls. (B) Max fluorescence signal of samples and controls.  Letters 
represent component combinations. B = bead, C = capture antibody, L = 
lysate, D = detection antibody, S = secondary antibody, * indicates lysate from 
recombinant FMRP.  
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Figure 5.11.  Immunofluorescence FMRP measurements versus cell density.  
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Figure 5.12.  Representative 20X images of rate hippocampal neurons plated at 
1MM cells/mL (A) FMRP specific marker. (B) DRAQ5 nuclear stain. (C) 2-
channel composite image. (D) Magnified view of composite image. Scale bar = 
250 µm.  
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Figure 5.13.  Representative 20X images of rate hippocampal neurons plated at 
500K cells/mL (A) FMRP specific marker. (B) DRAQ5 nuclear stain. (C) 2-
channel composite image. (D) Magnified view of composite image. Scale bar = 
250 µm  
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Figure 5.14.  Representative 20X images of rate hippocampal neurons plated at 
250K cells/mL (A) FMRP specific marker. (B) DRAQ5 nuclear stain. (C) 2-
channel composite image. (D) Magnified view of composite image. Scale bar = 
250 µm  
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Figure 5.15.  Representative 20X images of rate hippocampal neurons plated at 
0K cells/mL (A) FMRP specific marker. (B) DRAQ5 nuclear stain. (C) 2-channel 
composite image. (D) Magnified view of composite image. Scale bar = 250 µm  
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Chapter 6:  Conclusions 
 This work set out to determine whether or not microraft arrays represent a 
viable tool for expanding cellular throughput in drug screening for neurological 
disorders.  Previous work by Niedringhaus et al. using the microraft array for 
neuronal culturing and physiological measurement was very encouraging, but 
performed limited testing with traditional high-throughput screening tools such as 
high-density well plates and did not test the technology using a high-throughput 
formatted assay.  For this research, the microraft array was used to culture human 
and rat neurons in 384-well high-density plates.  New tools were created to 
transport, center, and secure the microrafts to facilitate screening, and scalable 
assays were devised in order to determine the feasibility of this technology in real 
screens for neurological disorders. 
 One of the biggest challenges in using the microrafts for cell-based screening 
is the manual handling of microrafts, as well as manually carrying out the processing 
steps of the described assays to extract useful data.  An advantage of the microraft 
array in neurological screening is the possibility of using this technology without the 
need of expensive automated equipment.  However, it was observed in this work 
that manual use of the microraft array for screening is difficult and impractical.  
Extracting the full potential of the microraft array requires seeding cells onto the 
device, releasing the individual microrafts, removing the microrafts and placing them 
one-by-one into individual wells of 384-well microtiter plates, supporting the 
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cellgrowth in a healthy manner, and then securing the microrafts with their attached 
neurons during assay processing steps such as washing, aspirating, and agitation 
etc.  Such choreography proved to be very difficult under manual conditions.  
Neurons are arguably the most sensitive cell type in our body and disturbing them 
after plating and attachment can cause aggregation, detachment, or even cell death.  
Therefore, mass release of the microrafts by flexural deformation of their PDMS 
substructure can lead to these outcomes and individual release of each microrafts is 
more beneficial. 
 Additionally, transferring single rafts is also very difficult to perform with the 
naked eye and is quite time consuming.  For these reasons, transferring microrafts 
individually with an automated approach is more beneficial.  As a future strategy to 
enable high-throughput screening using microraft arrays, a system was conceived 
that would improve the release and transfer of microrafts for screening purposes 
(see Appendix A.1-3); the fabrication of this system was beyond the scope of this 
project.  An automated system releasing and transferring the microrafts was 
developed by Attayek et al., however this system was designed specifically for 96-
well plates and operates at about 30 seconds per well with a single magnetic wand 
and microneedle.  The system sketched out in Appendix A would instead use 4x4 
array of microneedles and miniaturized magnetic wands with a 4.5 mm spacing to 
match the well-to-well spacing of the 384-well plate.  With this spacing, a customized 
microraft array (Figure A.1 A) would have to be produced such that the microrafts 
are released at the precise location of each magnetic wand tip.  Compared to the 
original microraft array used throughout this work, this customized array would be 
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smaller containing about half the number of total microrafts, but each microraft would 
be slightly larger at 550 µm on each side.  Using this customized system with the 
same 30 second cycle time of the previous 96-well automated system, a 384-well 
plate could be fully populated in approximately 12 minutes or less with 16 microraft 
transfers on each cycle. 
 Given the delicacy of neurons, assay procedures requiring washing and 
aspiration were very difficult to perform manually even with the security of the 
magnet array plate.  These steps required very careful technique and vision so as to 
not disturb the cells.  Such careful dexterity puts a lot of strain on the user, and thus 
fluid handling machines where fluid pressure and aspiration height can be specified 
are very much an advantage when using this technology.  For future studies, the 
integration of automated fluid handling machines with the microraft arrays could 
improve assay performance and reliability. 
 Provided there is the ability to work with the microraft arrays in a highly 
controlled automated environment, there is much promise for their ability to help 
expand screening for neurological diseases using human or primary neurons.  The 
future directions of this work include the design and implementation of a fully 
automated system that can successfully release and transfer single microrafts filling 
a 384-well plate in less than five minutes.  Such a system (Appendix A.1-3) would 
have to be utilized in concert with a traditional fluid handling machine and stem cell 
facility such that the sterility chain would remain intact.  Considering that assay 
development requires a very robust environment where many variables must be 
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tested in parallel and many plate layouts must be prepared, creating this automated 
system is critical in order to achieve desired results from appropriate sample sizes. 
Once the release and transfer of the microrafts is fully automated for 384-well 
microtiter plates, the next major hurdle for the commercial adoption of the microrafts 
in neurological screens is demonstrating their use in a scalable high-throughput 
assay.  In regards to this future assay development, a new more streamlined 
approach should be tested.  The bead-based ELISA used in this work coupled with 
flow cytometry measurements was selected for its high sensitivity.  However, this 
assay was very complicated to implement and requires extensive optimization and 
validation beyond the scope of this project.  In an effort to avoid such complications 
and expedite the detection of FMRP in a high-throughput assay, a much more 
streamlined approach should be tested in the future. 
In the previous study by Niedringhaus et al. the microrafts had been used to 
reproduce the results of an immunofluorescence screening assay originally used by 
Huang et al.1  This assay was developed to screen compounds for potential 
treatment of Angelman syndrome and concluded with topotecan, a topoisomerase 
inhibitor as a possible therapy.  In reproducing these results Niedringhaus et al. 
tested topotecan on embryonic neurons from a mouse model containing a Ube3a-
YFP transgene within the normally silent paternal allele on the microrafts, resulting in 
increased YFP expression indicating that topotecan indeed activated the normally 
dormant paternal allele of Ube3a.2  Although successfully reproducing the same 
results, this assay was based on high-content imaging which is typically not 
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considered “high-throughput” due to the extensive number of assay steps and the 
time required for image acquisition and analysis. 
For testing the microraft arrays in a high-throughput scalable assay a good 
model to replicate would be that of Kumari et al. published in Stem Cells 
Translational Medicine in 2015.3  In this study and assay was designed, optimized, 
and validated to measure increases in FMRP to identify potential drug candidates for 
treating fragile x syndrome.  This assay utilized TR-FRET to detect the presence of 
FMRP in a 1536-well plate format.  After first optimizing and validating the assay, a 
small screen was performed with the library of pharmacologically active compounds 
(LOPAC1280) which contains 1280 compounds, and then with an FDA approved drug 
library containing ~4,000 compounds.  As previously mentioned, none of these 
compounds produced FMRP at clinically relevant levels, however a proof of principle 
was established. 
TR-FRET is an attractive assay type because of its simplicity.  After seeding 
the cells and allowing them to attach and grow over night, compounds are 
introduced and incubated for 24 hours.  Following the compound introduction, the 
cells were lysed with 4X lysis buffer at 4°C for 30 minutes.  Then donor and acceptor 
antibodies were added and incubated simultaneously overnight at 4°C.  The next 
day, the plate was read using an Envision Plate Reader (Perkin Elmer) with an 
excitation of 320 nm, a donor emission of 615 nm and an accepter emission of 665 
nm.  In theory, this same procedure could be performed on a plate containing 
microrafts and would have much less complexity compared to the bead based 
ELISA.  This assay utilizes an anti-FMRP (clone 2D4)-K (Ab-7-K) donor antibody 
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with the Ab-K europium-cryptate donor fluorophore and anti-FMRP (D14F4)-d2 
acceptor antibody with the Ab-d2 acceptor dye.  Both of these antibodies are specific 
to the N-terminal of FMRP.   
Using purified recombinant FMRP at various concentrations, the dynamic 
range was reported as linear between 4 - 270 fmol/µL which equals approximately 
280 – 19,200 pg/µL.  The incubation time for these antibodies, and the cell plating 
density were then optimized using FXS patient fibroblasts cultured in 384- and 1536-
well plates.  Once these results were acquired the assay was tested on iPSC-
derived neural stem cells (NSCs) from FXS patients with the full mutation as well as 
healthy controls.  The NSCs and their controls were plated at densities of 625, 1250, 
2500, and 5000 cells per well in 1536-well solid bottom white plates and their FMRP 
levels were measured.  FMRP levels were reported as the ratio of the sample 
fluorescence signal to the control fluorescence signal.  Unfortunately the exact 
values of these measurements were not reported but judging by the graph 
published, it seems the following values represent an approximation of the raw data: 
 
After plotting these results (Figure 6.1), interestingly, it appears that the 
FMRP levels decrease in a logarithmic pattern as the cell density increases.  
However, compared to background levels this indicates that for small cell 
Cell Density 
(cells/well) 
FMRP Level (A.U.) 
625 38 
1,250 25 
2,500 20 
5,000 10 
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populations the gap between the signal and background diminishes.  With this 
assumption, fitting a logarithmic trend line results in a R2 = 0.974.  Using the 
equation of this line to estimate the FMRP levels for the average amount of cells on 
the microrafts (300-500 cells) results in a range of 46 – 39.5 which would still be less 
than half the signal produced from the healthy control which is represented by a 
value of 100. 
 
Figure 6.1.  FMRP measurements in NSCs using TR-FRET assay by Kumari et 
al. 
 After testing the assay on NSCs, Kumari et al. also performed tests on iPSC-
derived neurons plated in 1,536-well plates at a density of 2,500 cells/well.  This 
experiment resulted in an FMRP level of 40, which was double the value of the NSC 
experiments at the same cell density.  Therefore, assuming a similar logarithmic 
trend, the microraft might produce values of approximately 92 – 80 which is nearly 
indistinguishable from the control. 
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 Finally, to validate the assay for HTS, signal to background (S/B) ratios were 
calculated along with the coefficient of variation (CV) and Z’ scores.  These metrics 
were calculated for FXS iPSC-derived NSCs and FXS iPSC-derived neurons each 
plated in 1536-well plates at a density of 2,500 cells/well along with controls from 
healthy donors.  For the NSCs the S/B, Z’, and CV were 5.2, 0.4, and 9.5% 
respectively.  Assuming the same logarithmic relationship, for microrafts containing 
300 - 500 neurons the S/B would be approximately 2.5 - 2.2.  Since the distance 
between the signal and background is much narrower for 500 neurons, the Z’-factor 
will be reduced by the same proportions.  Thus for 300 – 500 cells on the microrafts 
would produce Z’-factors approximately equal to 0.19 – 0.17.  Although these 
numbers represent a very small separation band, performing a screen with the 
microrafts using this assay would still be possible.  It’s also possible that the CV 
values would remain the same. 
 In a study published prior to the Kumari paper, Schutzius et al. used a TR-
FRET assay in a similar fashion to detect FMRP; however, this study only focused 
on assay development and did not perform any compound screening.4  This study 
used an anti-FMRP 1C3 (Mab2160) donor antibody and an anti-FMRP (M03-d2) 
acceptor antibody – both specific to the N-terminal of FMRP like those used by 
Kumari et al.  Due to the tendency of purified recombinant FMRP to aggregate, 
recombinant FMRP was fused with maltose binding protein (MBP-FMRP) for use in 
optimizing the assay.  Using this MBP-FMRP, the antibody combination, and an 
Envision plate reader, a linear dynamic range was reported between 10 – 2000 
pg/µL. 
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After optimization, to investigate if the assay was capable of quantifying 
endogenous human FMRP, batch lysates from FXS patient-derived fibroblasts and a 
healthy human control were tested.  These cells were plated at various cell densities 
ranging from 500 – 8,000 cells/well in 384-well plates, and the Z’-factors were 
reported.  At 8,000 cells per well Z’ = 0.85 whereas for 500 cells per well Z’ = 0.03.  
Since these tests were performed on fibroblasts, it’s difficult to interpolate them to 
neurons, but based on these results and the estimates from the findings of Kumari et 
al., it’s reasonable to assume that a screen performed with 500 neurons on 
microrafts would result in a Z’-factor less than 0.5 which is the standard benchmark 
above which an assay is considered excellent and simply “screenable” when this 
value falls between 0 and 0.5.  Moreover, at the wells plated with 500 fibroblasts 
produced a change in fluorescence equal to  
Finally, in order to test the feasibility of using microraft arrays with hiPSC-
derived neurons, future experiments growing these cells on the microraft arrays 
should be conducted.  These experiments should test neuron viability over time, 
neurite outgrowth, as well as electrophysiological cues and synaptic function 
compared to the same cells grown directly in 384-well plates.  Moreover, various 
protocols should be tested in parallel to determine the various kinds of neurons that 
can be differentiate on the microrafts working with 384-well plates.  Knowing the 
types of neurons which can be produced on the microrafts is important in further 
demonstrating their utility as a tool for neurological drug screening. 
 At present, the microraft array is very challenging to use.  However, the 
benefits it promises, namely a >20 fold increase in throughput with 384-well plate 
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compatibility, suggest that implementing the above changes beyond the current 
scope of work will help unlock its true potential as a screening tool.  Moreover, 
based on previous work there is evidence that this technology could be used with a 
TR-FRET based high-throughput screening assay further validating its potential. 
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APPENDIX 
 
 
Figure A.1.  Modified microraft array design for 384-well automation. (A) 
Original microraft design used in all experiments. (B) Redesigned microraft 
array for automated release and transfer to 384-well plates  
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Figure A.2.  Custom magnetic wand array design for 384-well automation. (A) 
Profile view showing magnetic wands attached to a single substrate. (B) 
Detailed view of individual magnetic wand design featuring a free moving 
magnet within a sealed tube for capture and release of microrafts. (C) Plan 
view of 4x4 magnet wand array with 4.5 mm spacing to match spacing of 384-
well plate.  
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Figure A.3.  Schematic of 384-well Cellraft release and transfer process. (A) 
Release of individual microrafts with a 4x4 microneedle array with 
simultaneous capture via magnet wand array. (B) Release of microrafts from 
magnet wand array via magnetic repulsion using the magnet array plate. 
 
